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Abstract 
Background: Annually over 225,000 individuals are diagnosed with lung cancer and over 
80,000 undergo surgery with many experiencing concurrent post-operative symptoms. 
Objectives: The purposes of this study were to: 1) describe the symptom experience during the 
first year following lung cancer surgery, 2) explore relationships between symptoms, influencing 
factors and functional performance, and 3) compare responses in patients with and without 
PTPS. Methods: This descriptive, cross-sectional, correlational study was guided by the Theory 
of Unpleasant Symptoms (TOUS). Patients were recruited over 28 months from a university 
medical center and subsequently completed the following six self-report instruments: the 
Symptom Distress Scale, McGill Pain Questionnaire, Neuropathic Symptom Questionnaire, 
Hospital Anxiety and Depression Scale, the Health History Survey and Functional Assessment of 
Cancer Therapy-Lung; medical record reviews were conducted to corroborate responses. 
Spearman’s rho was used to measure relationships among variables. Comparisons between 
participants with and without PTPS were made using Chi-Square or Fisher’s exact test. 
Significance was set at p < .05. Results: Patients were assessed on average 6 months after 
surgery, and were predominantly diagnosed at cancer Stage I, elderly, female, Caucasian, 
educated at the high school level with mild to moderate psychiatric distress, and at least five 
comorbid conditions. The majority reported distress associated with concurrent symptoms. 
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Patients with more psychiatric distress reported more symptom distress and patients with higher 
symptom distress reported lower functional performance. Patients who were younger, had some 
mood disorder and decreased functionality were significantly more likely to report PTPS. 
Conclusions: Patients reported distress associated with a wide range of concurrent post-
operative symptoms, including PTPS.  The TOUS may assist clinicians to explore relationships 
that are important for the assessment and management of symptoms after surgery for lung 
cancer. 
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1.0  INTRODUCTION 
Globally, lung cancer claims more lives each year than colon, prostate, ovarian, lymph, and 
breast cancer combined (American Cancer Society, 2014). Although often diagnosed late, 
expected survival following the diagnosis of Stage I lung cancer is 52.9% at five years if 
confined to the primary site (American Cancer Society, 2014). New innovative minimally 
invasive surgical techniques reduce the necessity of open chest thoracic surgery for lung cancer 
(Karasaki, et al. 2009; Keenan et al., 2004). Even with less invasive approaches, as many as 50% 
of patients continue to experience symptoms related to the surgical procedure for months or 
years (Karasaki, et al. 2009; Keenan et al., 2004).  
A primary outcome, termed post-thoracotomy pain syndrome (PTPS), is defined as pain 
that recurs or persists along a thoracotomy incision at least two months after the surgical 
procedure (International Association for the Study of Pain, 2011; Merskey, 1986). PTPS has 
been attributed to rib or nerve damage from surgery or a chronic pain syndrome initiated by 
inadequate pain relief in the postoperative period (Chapman, 2011; Wildgaard et al., 2011). 
Typically described as aching, burning, or extreme sensitivity to touch at or near the scar or chest 
tube insertion site, the etiology of PTPS is thought to be distinct from acute post-operative pain, 
side effects of treatment, or cancer progression (American College of Chest Physicians, 2013; 
Wildgaard et al. 2011; American College of Chest Physicians, 2007). 
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In addition to pain, patients often experience multiple and concurrent symptoms after 
thoracotomy, including: dyspnea, fatigue, and depression (Sarna et al. 2010; Sarna et al. 2008). 
Anti-cancer treatments such as surgery, chemotherapy and radiation also influence the type and 
pattern of concurrent symptoms (American College of Chest Physicians, 2013). In spite of these 
possible explanations, patients often mistakenly worry that their post-surgical symptoms are due 
to cancer recurrence, a belief that creates anxiety and compromises Quality of Life (QOL) 
(Chapman, 2011). Initiatives are needed to assist patients with lung cancer who are challenged 
by the physical and emotional impact of these troubling symptoms.  
Historically, the majority of symptom research regarding lung cancer has been limited to 
patients with metastatic disease (Cleary et al, 2008; Dajczman, Gordon, Kresisman, & Wolkive, 
1991) and complications following chemotherapy (Myers, 2009) and radiation (Pituskin et al., 
2010). There continues to be little insight into managing symptoms experienced by patients who 
undergo potentially curative surgical treatment (Demmy, 2009; Landreneau et al., 1994). The 
paucity of information available makes identifying interventions to support patients during their 
surgical recovery a challenge (Sarna et al., 2010; Sarna et al., 2005). 
1.1 PURPOSE 
The purposes of this descriptive, cross-sectional, correlational study were to describe the 
symptoms experienced by patients in the first year following lung cancer surgery; explore the 
relationships between symptoms, the factors that influence them and the effect of symptoms on 
performance, and to compare these responses in patients with and without PTPS. Because the 
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symptom experience after surgery for lung cancer is complex and patients typically report 
multiple concurrent symptoms, the Theory of Unpleasant Symptoms (TOUS) (Lenz, Pugh, 
Milligan, Gift, & Suppe, 1997), a model that incorporates the multidimensionality of the 
symptom experience, was selected as the guiding framework for this study. 
1.2 SPECIFIC AIMS 
The aims of the study were to: 
Aim 1. Describe the physiologic, psychologic and situational influencing factors, the symptoms, 
and performance outcomes. 
Aim 2. Determine the strength of the associations between physiologic, psychologic situational 
factors and patients’ symptom(s).  
Aim 3. Determine the strength of the associations between symptom(s) and patients’ 
performance.  
Aim 4. Compare the symptom experience, the factors that influence the symptom experience  
and the impact of symptoms on performance between patients with and without PTPS after 
surgery for lung cancer. 
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2.0  BACKGROUND, SIGNIFIANCE, AND INNOVATION  
2.1 BACKGROUND 
The typical symptoms of lung cancer, cough, hemoptysis, and pain, commonly occur in 
advanced stages of the disease. Lung cancer at an earlier stage is often detected incidentally 
during a chest x-ray for pneumonia, following an accident, or other event (American Cancer 
Society, 2014). This finding triggers a referral to a thoracic surgeon who reviews the x-ray and 
clinical data to assess risk for a possible malignancy (National Comprehensive Cancer Network, 
2012; Groome & Bolejack, 2007). If warranted, further diagnostic testing such as radiologic 
imaging, endobronchial ultrasound, or tissue biopsy using transthoracic needle aspiration or 
bronchoscopy are performed to determine cell type, stage, and guide clinical management 
(National Comprehensive Cancer Network, 2012; Memoli-Wang et al., 2011; Wiener, Schwartz,  
Woloshin, & Welch, 2011). Clinical staging is based upon the tumor size (T), the number and 
location of involved nodes (N) and number of metastatic sites (M) determined from pre-
operative imaging and biopsy (National Comprehensive Cancer Network, 2012). 
There are several cell types identified as lung cancer and, of these, adenocarcinoma and 
squamous cell cancer are the most common (American Cancer Society, 2014).   Lung cancer is 
classified as non-small cell (NSCLC) (80%) and small cell (SCLC) (20%) (The National Lung 
Screening Trial Research Team, 2010). SCLC is typically more aggressive and often found in 
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later stages when it has metastasized to other sites (National Comprehensive Cancer Network, 
2012). Therefore, surgery is typically not an option for treating SCLC. 
Treatment for lung cancer depends upon tumor histology (cell type) and extent (stage) 
(Groome & Bolejack, 2007) and patient related factors (age, pulmonary function, comorbidity) 
(Keenan et al., 2004; Landreneau et al., 1994). Surgery offers the only curative option and 
therefore is the treatment of choice for those with localized non-small cell lung cancer NSCLC, 
(Stage I, II or possibly IIIa) (American Cancer Society, 2014) and enough cardio-pulmonary 
reserve to tolerate removal of the necessary amount of lung parenchyma. Approximately 30% of 
patients with lung cancer meet these criteria and undergo surgery (Wildgaard et al., 2011; 
Landreneau et al., 1994). The purpose of surgery is first to remove the tumor and examine the 
margins to ensure no cancer cells remain, and second to remove appropriate lymph nodes to 
investigate spread to the lymphatic system (Rodger & Duffy, 2000; Landreneau et al., 1994). The 
options for surgical approaches include a standard thoracotomy or a thorascopic procedure, also 
termed video assisted thoracic surgery (VATS) (National Comprehensive Cancer Network, 
2012; Groome & Bolejack, 2007). 
A thorascopic procedure is considered to be minimally invasive because the approach 
does not involve rib-spreading and only requires three small, one to five centimeter incisions or 
ports (Park et al., 2011; Rodger & Duffy, 2000). Figure 1.  Incisions are typically in a triangular 
shaped array (Karasaki et al., 2009). These incisions are strategically placed to permit insertion 
of the fiber optic video camera (endoscope), instruments to inflate the chest cavity, and other 
holding and cutting surgical instruments (Rodger & Duffy, 2000). In some cases, a VATS 
procedure may need to be converted to a full thoracotomy if unexpected issues arise during the 
6 
surgery (e.g. more aggressive carcinoma) (Park et al., 2011; Boffa et al., 2008; Aoki, Tsuchida, 
Hashimoto, Saito, Koike, & Hayashi, 2007). 
Figure 1. Illustration of scar location after thorascopic surgery (Photo courtesy of Dr. Rodney 
Landreneau) 
Thoracotomy for lung cancer, the more common (Karasaki et al., 2009; Boffa et al., 
2008) and invasive (Boffa et al., 2008; Keenan et al., 2004) approach, requires a larger surgical 
incision between the ribs that is typically six to 12 centimeters in length (Rogers & Duffy, 2000). 
After the incision, rib spreaders are used allowing a much larger entry into the chest wall and 
intercostal cavity. This procedure is known to cause injury to the costochondrial junction, ribs, 
cartilage, (Wildgaard et al., 2011), intercostal nerves (Wiener, Schwartz, Woloshin & Welch, 
2011; Keenan et al., 2004), and latissimus dorsi muscle (Karasaki et al., 2009; Keenan et al., 
2004) (Figure 2).  
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Figure 2. Illustration of scar location after a thoracotomy (Photo courtesy of Dr. Rodney 
Landreneau) 
  
Regardless of the approach, surgery involves instrumentation that passes through major 
chest muscles, intercostal spaces, ribs, nerves, and pleural cavity (Park, 2011; Boffa et al., 2008).  
Surgical sequelae include atrophy of chest muscles (Boffa et al., 2008), chronic pain from injury 
to intercostal nerves (Pettunen, Tasmuth, & Kalso, 1999; Landreneau et al., 1994), and fractured 
and compressed ribs (Landreneau et al., 1994) to name a few (Rogers & Duffy, 2000). Upon 
healing, the only external visual reminders are the consequent scars. While some patients recover 
with no untoward consequences, others experience pain that recurs or persists along a 
thoracotomy incision at least two months after the surgical procedure, a condition known as 
PTPS (Wildgaard et al., 2011; Perttunen et al., 1999; Landreneau et al., 1994).  
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2.1.1 Post Thoracotomy Pain Syndrome (PTPS) 
First described in 1944, PTPS received limited attention until 1991 when a seminal study 
surveyed 56 patients with lung cancer who were disease free up to five years after thoracotomy 
(Dajczman et al., 1991). Despite their long-term, disease free status, 54% of the sample reported 
PTPS (Dajczman et al., 1991). Other studies found PTPS to be present in 11–80% of patients, 
confirming that PTPS is a common complication (Corte, Mendola, Messina, & Cammarota, 
2011; Duale et al., 2011; Sikorskii et al., 2007; Dajczman et al., 1991). Notably, although PTPS 
is common, not all patients who undergo lung cancer surgery develop PTPS suggesting different 
causative factors (Demmy, 2009; Karasaki et al., 2009; Shaw & Keefer 2008; Max et al., 2006). 
Etiology of PTPS  
The etiology of PTPS has been attributed to rib (Bayram, Ozcan, Kaya, & Gebitekin, 
2011), nerve (Miyazaki et al., 2011; Benedetti et al., 1998), or muscle (Karasaki et al., 2009; Lia 
et al., 2003) damage from surgery or a chronic pain syndrome initiated by inadequate pain relief 
in the post-operative period (Wildgaard et al., 2012; Demmy, 2009). Other potential causative 
mechanisms include nerve or muscle damage related to the insertion of chest drainage 
mechanisms, e.g. chest tubes and Jackson Pratt (JP) tubing (Corte et al., 2011; Benedetti et al., 
1998; Landreneau et al., 1998; Landreneau et al., 1994) and any instruments or drainage devices 
passing through the network of intercostal nerves that have the potential to cause nerve damage 
resulting in chronic neuropathic pain (Corte et al., 2011).   
Prior to the advent of minimally invasive surgical techniques, PTPS was presumed to be 
attributed to the extent of the thoracotomy incision and the methods for pain relief achieved 
following surgery (Wildgaard, Ravn, & Kehlet, 2009).  However, in one of the first reports 
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comparing outcomes following these surgeries, Landreneau and colleagues (1994) enrolled 343 
consecutive patients undergoing a thoracotomy (n=165) or a thorascopic procedure (n=178) and 
found no significant difference in chronic pain levels between the two groups (Landreneau et al., 
1994). Landreneau et al., used a scale of one (no pain) to ten (most severe pain ever) when 
comparing pain ratings. The design of this study did not involve matching between groups, a 
limitation of this study. More recently, Furrer and colleagues (1997) matched 15 thorascopic 
lobectomy patients with 15 patients who underwent a lobectomy with the more aggressive 
thoracotomy on age, gender and preoperative pulmonary function and found that 36% of the 
thorascopic and 33% of the thoracotomy group reported pain using a scale of one (no pain) to ten 
(most severe pain ever) (Furrer et al., 1997).   Additional studies that examined potential 
mechanisms for PTPS and strategies for prevention have reported persistence of pain in patients 
who underwent either procedures (Wildgaard et al., 2012; Karasaki et al., 2009; Aoki et al., 
2007; Furrrer et al., 1997).  Findings of these studies provide additional evidence that PTPS is 
not solely related to the type of surgical procedure.  
To further explore this syndrome, several studies have investigated muscle function 
following both surgical procedures.  Frola and colleagues’ study of 58 patients who underwent 
thoracotomy analyzed computed tomography (CT) scans taken before and after surgery. They 
reported that 40 participants had chest wall symmetry and atrophy in chest wall muscles 
simultaneously, 16 had no atrophy and 2 had atrophy in the serratus anterior muscle only (Frola 
et al., 1995).  More recently, Karasaki and colleagues (2009) reported results of CT scans in 70 
patients presenting with PTPS within 3 months after surgery. Of these, 53 had a thoracotomy and 
17 had thoracoscopic surgery. Subjects reporting PTPS had an increase in muscle wall density. 
However, cross-sectional measurements of the latissimus dorsi muscle indicated that this muscle 
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was better preserved on the surgical side in patients who underwent a thorascopic procedure, 
compared to patients who underwent a standard thoracotomy (Karasaki et al., 2009). Although, 
this study concluded that thoracoscopic surgery may prevent atrophy, the sample was small and 
included a disproportionate number of participants with the two procedures (Karasaki et al., 
2009). 
PTPS literature is difficult to summarize due to methodological issues. In a recent review 
of PTPS mechanisms and strategies for prevention, Wildgaard et al. (2009) reported several 
inconsistencies in sampling methods and methods used to determine the presence of PTPS and 
related symptoms (Wildgaard et al., 2009). Some studies rated the presence and intensity of pain 
based upon a visual analog scale (VAS) whereas others retrospectively measured pain intensity 
based upon patients’ consumption of analgesics (Demmy, 2009; Keskinbora, Pekel, & Aydinli, 
2007). Other studies used descriptors such as aching, burning, tender and numbness (Maguire et 
al., 2006; Kalso et al., 1992). Some studies assessed preoperative anxiety and depression using 
researcher-developed questionnaires (Katz & Seltzer, 2009; Maguire et al., 2006). From their 
review, Wildgaard and colleagues (2009) concluded that intercostal nerve injury was the “most 
important pathologic factor responsible for the development of PTPS” (Wildgaard et al., 2009, 
p.172). 
The most commonly cited definition of PTPS was first published by the International 
Association for the Study of Pain (IASP) in 1986 with little modification (International 
Association for the Study of Pain, 2011; Merskey, 1994; Merskey, 1986).  Others have expanded 
this definition to include: “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage” (Patel, 2010, p.3). This 
expanded definition notes presence of a chronic and unpleasant sensory and emotional 
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experience after surgery not related to metastasis, inflammation, or other non-surgically related 
causes.   
The search for physiologic explanations for PTPS has dominated the literature. Of 
interest, there has been limited attention paid to the potential influence of psychological or 
situational factors on this syndrome. In addition to the trauma of surgery, thoracic surgery 
patients may also experience physiological, psychological, and social changes due to their 
disease process (Gray, 2008; Williams, 2006; Landreneau et al., 1994). Sarna and colleagues 
(2010) noted pain related to PTPS often co-occurred with dyspnea (21%) and depression (29%) 
(Sarna et al., 2010). Co-morbidities involving pulmonary and cardiac disease are common in this 
population and these etiologies may be sources of pain. As a consequence, PTPS is difficult to 
diagnose, optimally manage and therefore is often under treated. 
Assessment of PTPS  
When patients present for follow-up post-surgical visits, a comprehensive assessment has 
been recommended to detect the presence of PTPS. During post-surgical clinic visits, surgeons 
and clinicians should inquire if patients continue to experience pain and, if so, ask them to rate 
their discomfort on a scale from one to ten (Wildgaard et al., 2011; Herr, 2004). The surgical 
area should be examined for inflammation of the chest muscles (Benedetti et al., 1998) and 
evidence of tissue, nerve, or muscle damage (Wildgaard et al., 2011; Benedetti et al., 1998). A 
full range of motion should be performed to detect any evidence of PTPS and documented in the 
medical record (Herr, 2004; Benedetti et al., 1998).  
Rating PTPS (Pain or Neuropathy) 
The early focus on pain as an explanation of the discomfort that occurs with PTPS, has 
more recently been expanded to other possible explanations. Findings of recent studies that 
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employ more comprehensive rating system; they focused on neuropathy and requires a physical 
exam that includes pricking  patients with pointed instruments at the healing incision site, which 
was not allowed by the surgical group in this sample (Mongardon et al., 2011; Krause, & 
Backonja, 2003); Snaith, & Zigmond, 1994).Studies suggest that PTPS maybe neuropathic in 
origin, an outcome attributed to nerve damage caused by the instruments during the surgery, the 
percentage of patients reporting slight or mild pain and the patient’s pain descriptors (Bayram et 
al., 2011; Miyazaki et al., 2011). The surgical origins of neuropathy are believed to occur when 
an axon is cut (nerve injury) and the distal portion forms a terminal swelling or end-bulb from 
which axonal buds or sprouts emerge. These sprouts can form a neuroma, a major source of 
ectopic impulse generation and therefore neuropathic pain (Herr, 2004; Gould et al., 2000). 
PTPS pain descriptors that resemble descriptors associated with neuropathic pain include 
numbness, tingling, and discomfort (Wildgaard et al., 2011; Herr, 2004). Therefore, ratings 
scales that attempt to capture symptoms caused by neuropathic pain are increasingly being 
included in measures of the discomfort from PTPS. 
Pain ratings do not appear to differ depending on the type of surgical procedure. In the 
previously cited study, Furrer and colleagues (1997) reported that patients undergoing a 
thorascopic procedure and thoracotomy reported pain and neuropathic-like descriptors, e.g., pain 
that was “pleuritic or aching in nature” (Furrer et al., 1997, p. 1082). Postoperative ratings 
reflected mild pain (range 0.2 to 1.6 on a 10 point scale) and did not differ significantly with 
activities (Furrer et al., 1997). The prevalence of pain was similar to those reported by Dajczman 
and colleagues (1991) who asked 56 patients who underwent lung cancer surgery to rate their 
pain using a ten cm Visual Analog Scale (Dajczman et al., 1991). Dajczman and colleagues 
reported in 40%, 44.8%, and 37.5%,, of patients at one, two and three years after thoracotomy, 
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respectively (Dajczman et al., 1991). Gotoda and colleagues (2001) used a four point, Likert-
type scale to assess post-thoracotomy pain within the first year, (i.e., none, slight, moderate, and 
severe), and found that 70.6 % of patients reported PTPS and 56.7%, rated their pain as slight, 
23.3% as moderate, and 20% as severe (Gotoda et al., 2001). They further noted that respondents 
reported symptoms that indicated nerve impairment rather than simple muscle damage with this 
syndrome (Gotoda et al., 2001).    
More extensive exploration has supported the presence of symptoms commonly 
associated with neuropathy and suggested a timeline for development. Duale and colleagues 
(2011) surveyed 73 post-operative pneumonectomy patients who were divided into two groups - 
those who did or did not receive perioperative ketamine (Duale et al., 2011). The patients’ 
pain/sensitivity were assessed immediately post-operatively and again at week four and six, 
using a VAS (100 mm line) measuring sensitivity to the touch of the blunt end of a paintbrush. In 
addition, pain/sensitivity was measured at the scar area using an electronic algometer for 
mechanical threshold and Somedic Thermo test apparatus applied to measure thermal thresholds 
(Duale et al., 2011). Duale and colleagues (2011) concluded that neuropathy, at the second week, 
did not predict pain six weeks after surgery and “…thoracotomy often induced intercostal 
neuropathy that develops between the second and the sixth week after thoracotomy, with varying 
consequences” (Duale et al., 2011, p.252). Based on this work, Duale and colleagues (2011) 
concluded that both pain and neuropathic symptoms should be included in the definition of PTPS 
(Duale et al., 2011).  
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2.1.2 Theoretical Framework 
Several theoretical frameworks focus on the symptom experience and opportunities to manage 
symptoms.  Dodd’s Symptom Management Conceptual Model, also known as the University of 
California-San Francisco School of Nursing Symptom Management Model (UCSF-SSM) is 
comprised of three interrelated dimensions: symptom experience, symptom management 
strategies and outcomes (Dodd et al., 2001). The UCSF model depicts symptoms in terms of 
three domains (person, environment, and health) and thus has been useful in identifying areas to 
target for management of symptoms (Peterson & Bredow, 2009). Although the UCSF model is 
multidimensional it does not reflect the presence and potential interaction of multiple concurrent 
symptoms, and thus may be less useful for studying the complex and multiplicative symptoms  
commonly reported among patients who have undergone surgery for lung cancer (Teel, Meek, 
McNamara, & Watson, 1997).   
In the proposed research, determining an individual's interpretation of symptoms is 
critical to understanding the participant’s symptom management decisions. Another model 
known as the Symptom Interpretation Model (SIM) was developed to facilitate the subjective 
understanding of symptoms from an intrapersonal perspective (Teel et al., 1997 To understand 
the participant’s symptom experience, this model focuses on an individual’s knowledge and the 
meaning of his or her symptoms.  The symptom experience is viewed as multi-dimensional and 
includes sensory, affect, and cognitive elements. The SIM model has three major constructs: 
input, interpretation, and outcome (Teel et al., 1997).  Input is the subject’s recognition of the 
symptom. Interpretation is the participant’s meaning attached to the symptom and outcome is the 
participant’s decision-making result of the first two constructs. The SIM model is an expansion 
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of the UCSF-Single Symptom Model. However, it does not include an assessment of the impact 
of the patient’s decisions and actions on performance. 
The Theory of Unpleasant Symptoms (TOUS) includes three major concepts: concurrent 
unpleasant symptoms, the influencing factors that give rise to the nature of symptoms, and the 
impact of these symptoms on performance (Figure 3) (Lenz et al., 1997). Symptoms are 
described in terms of four dimensions: timing, distress, quality and intensity (Pituskin et al., 
2010; Eaton & Tipton, 2009; Lenz et al., 1997). Influencing factors are the interrelated aspects 
that influence the symptom experience and include three domains: physiologic, psychologic, and 
situational factors. Symptoms, the central focus of the model, are defined as the “red flags” or a 
perceived indicator of change in a patient’s normal functioning  (Lenz et al., 1997; Lenz, Suppe, 
Gift, Pugh & Milligan, 1995; Hegyvarym, 1993). Performance refers to the consequences of the 
symptom experienced such as the impact on function, cognitive ability and QOL (Chapman, 
2011; Lenz et al., 1997). 
The TOUS was selected as the theoretical framework for this study over the 
aforementioned symptom models because the TOUS: 1) focuses on patients’ subjective 
descriptors of unpleasant symptoms that occur alone or concurrently, 2) attends to the 
multidimensionality of symptoms, 3) makes the relationships between  influencing factors, 
symptoms and performance explicit. Thus, the TOUS was ideally suited to guide this study 
because factors underlying development of PTPS are poorly understood, symptoms can co-
occur, vary in onset, intensity and distress, and cause varying performance limitations.  
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Figure 3. The Theory of Unpleasant Symptoms (TOUS) (Printed with permission from: 
Wolters Kluwer Health and RightsLink) 
The following section organizes the literature related to symptoms after surgical 
treatment of lung cancer by concepts and relationships supported in the TOUS.  
Symptoms 
Symptoms reflect the individual’s subjective and perceptual processes that assign 
meaning to the unpleasant experience or sensation (Brown, Cooley, Chernecky, & Sarna, 2011).  
Reviewing studies which reported multiple and concurrent symptoms, we noted the following. 
Lee et al. 2005 in a cross-sectional, correlational study of 125 women considered mood 
disturbances using the Linear Analogue Self-Assessment Scale for mood and Symptom 
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Experience Scale (SES) for symptoms. They reported that mood disturbance significantly 
accounted for the variance in symptom experience (< 0.001) (Lee, 2005).  
Sarna and colleagues (2008) also reported this interrelationship in their survey of 94 
patients 4 months after lung cancer surgery. This study noted multiple symptoms including 
fatigue (57%), dyspnea (49%), cough (29%), and pain (20%), were compounded in participants 
with significant mood distress (Sarna et al., 2008). 
With respect to PTPS, prior studies (and the clinical experience of the Principal 
Investigator (PI), indicated that most patients do not mention pain from PTPS unless directly 
questioned (Demmy, 2009). When questioned, pain is typically described as aching (Chapman, 
2011; Rogers & Duffy, 2000; Furrer et al. 1997)  or burning (Merskey, 1986; Rogers & Duffy, 
2000); that may be aggravated by touch (Wildgaard et al., 2012); or movements of the shoulder 
girdle (Karasaki et al., 2009; Perttunen et al., 1999; Frola et al., 1995); and rated as mild to 
moderate in severity (Dajczman et al., 2008; Rogers & Duffy, 2000; Perttunen et al., 1999). 
Neither muscle sparing surgery (Karasaki et al., 2009; Frola et al., 1995; Landreneau et al., 1994) 
nor VATS (Rogers & Duffy, 2000; Furrer et al., 1997; Landreneau et al., 1994) reduced the 
incidence of PTPS (Furrer et al., 1997; Landreneau et al., 1994).  While important, a focus on 
aspects of the surgical procedure is likely inadequate in describing PTPS and other patient 
symptoms (Chapman, 2011; Landreneau et al., 1994). Lung cancer often occurs in older adults 
with a long history of smoking (American Lung Association, 2008). These cancer patients often 
bring additional psychological factors due to their personal history of smoking which may 
impact their perceptions of PTPS and other symptoms (American Cancer Society, 2014; Siegel, 
Ward, Brawley, & Jemal, 2011; Howlader et al., 2010; American Lung Association, 2008). 
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Sarna and colleagues (2008) surveyed 94 patients four months after lung cancer surgery. 
Symptoms noted in this sample included fatigue (57%), dyspnea (49%), cough (29%), and pain 
(20%).  
 
Influencing Factors 
 Studies suggest an interrelationship (or feedback loop) between physiologic, psychologic and 
situational factors and symptoms.    
Physiologic Influencing Factors 
Comorbidities are common and likely contribute to PTPS, e.g. pain from arthritis, 
dyspnea due to cardiac or pulmonary dysfunction can increase one’s sensitivity to PTPS 
(Chapman, 2011; Keenan et al., 2004). Two factors, inadequate acute pain relief (which may 
create a chronic pain state) (Demmy, 2009; Dodd et al., 2001; Rogers & Duffy, 2000, Teel et al., 
1997) and nerve/rib damage from the surgical procedure (Rogers & Duffy, 2000; Landreneau et 
al., 1994), are most commonly cited as physiologic mechanisms responsible for PTPS 
(Wildgaard et al., 2009; Gould et al., 2000; Rogers & Duffy, 2000). Current protocols 
aggressively target pain; hence, recent studies report low pain ratings (Rogers & Duffy, 2000; 
Landreneau et al., 1994; Dajczman et al., 1991). Notably, PTPS pain descriptors resemble 
descriptors associated with neuropathic pain (International Association for the Study of Pain, 
2011; Chapman, 2011;  Merskey & Bogduk, 1994; Merskey, 1986). Nerve injury may be due to 
the laceration of an axon during surgery. This nerve injury is a possible source of ectopic 
impulse generation and therefore, neuropathic pain (Duale et al., 2011; Herr, 2004; Gould et al., 
2000).  
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Psychologic Influencing Factors  
Anxiety and depression are also thought to influence symptoms in persons who undergo 
surgery for lung cancer. When Sarna and colleagues (2010) expanded their study to 119 women 
who were disease free up to six years after lung cancer surgery, depressive symptoms remained 
common (29%) and influenced QOL ratings (Sarna et al., 2010). Several studies have explored 
interventions to minimize psychologic symptoms (Myers, 2009; Jamsen et al., 2008; Sarna et al., 
2008; Sikorskii et al., 2007; Prasertisri et. al., 2011; Gift et al., 2004). Myers (2009) reported 
variable effects of chemotherapy-related changes in cognitive function that often increases 
anxiety in patients diagnosed with cancer (Myers, 2009). Myers’ review of the literature, 
reported that the TOUS as an appropriate model for describing the symptom experience related 
to mild to moderate changes in both cognitive impairment and the potential resulting increases in 
anxiety as described by both Aoki, Tsuhida, and colleagues (2007) and Prasertsri and colleagues 
(2011) (Prasertisri et. al., 2011; Aoki et al., 2007). 
Situational Influencing Factors  
Race and socioeconomic status appear to be a social determinants of pain and survival in 
lung cancer patients, with a large national study of (n = 248,741) lung cancer patients,  
reportedAfrican American, American Indian and Alaskan native, and Hawaiian natives having 
higher levels of pain and lower survival rates (Clegg et al., 2002). Asian Americans and Non-
Hispanic Caucasians were typically diagnosed at a later age than other ethnic groups or racial 
groups (Clegg et al., 2002). Similarly Fogel and Fogel (2003) reported that factors, such as 
marital status, employment status and income may also affect symptoms (Fogel & Fogel 2003).  
Performance  
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Effective management of unpleasant symptoms aims to reduce symptom severity and 
frequency in order to improve outcomes such as functional performance and enhanced quality of 
life. Merskey and Portenoy were two of the first researchers to measure the influence of pain on 
performance and QOL in cancer patients QOL(McGill, 2009; Portenoy & Kanner, 1997; 
Portenoy, 1990; Merskey, 1986). Other researchers examined the influence of symptoms on 
performance and QOL (Sarna et al., 2010; Sarna et al., 2005) and found that depressed mood, 
comorbidities, and dyspnea were related to poorer physical and emotional QOL (Sarna et al., 
2010).  Chapman (2011) noted that chronic pain had a significant effect on a cancer survivors' 
QOL. 
In summary, while important, a focus on aspects of the surgical procedure is likely 
inadequate in describing patient symptoms after surgery, including PTPS (Chapman, 2011; 
Landreneau et al., 1994). No prior studies were identified that comprehensively explored the 
symptom experience of persons who underwent surgery for lung cancer, the factors that 
influence the experience, or the relationships between symptoms and performance.  
2.2 SIGNIFICANCE 
Symptom assessment and managements targeted to improve post-operative recovery following 
lung cancer surgery tend to be intensive in regard to the use of resources and personnel (Cleary 
et al., 2008; American College of Chest 2007; Sikorskii et al., 2007; Logue, 2006; Herr, 2004), 
thus limiting translation into clinical practice. With patient encounters becoming increasingly 
brief (Sikorskii et al., 2007; Herr, 2004; Huang et al., 2003), there is an urgent need to ensure 
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consistent and optimal symptom assessment and management for patients recovering from lung 
cancer surgery. In the clinic where data were collected for this study, the average time patients 
with lung cancer spend in a clinic visit is ten minutes, a finding that mirrors national averages 
and suggests tremendous potential for patient centered educational tools to be developed based 
on findings from this study (Murray, Burns, See, Lai, & Nazareth, 2005; Fogel & Fogel, 2003). 
The TOUS provides a comprehensive framework to guide exploration of the symptom 
experience of patients who undergo early stage lung cancer surgery and the complex and 
challenging problem of both concurrent symptoms and PTPS. This framework was used to 
explore patient reported symptoms, influencing factors and outcomes with the goal of 
understanding the impact of surgical treatment on symptoms, patient functioning and well-being 
and guide the development of future interventions. 
Thoracic surgery, clinicians have historically viewed PTPS as a  “pain” only symptom 
with an unknown orgin, managed using traditional opioid modalities for relief, and morphine as 
the “gold standard” (International Association for the Stidu of Pain, 2011; Demmy, 2009; 
Perttunnen, Tasmuth, & Kalso, 1999). Historically, opioids have not provided adaquate releif 
(Wildgaard et al., 2011; Williams, 2006)  and unconrolled pain is a known risk factor for PTPS. 
Today, in addition to opiods both antidepressants and GABA analog medications are now 
available and being prescribed for these patients (Ballantyne, 2010; Keskinbora, Pekel, & 
Aydinli, 2007; Mattia, Paoletti, Coluzzi, & Boanelli, 2002).  Views are changing and clinicians 
are beginning to view PTPS as a complex syndrome which includes concurrent symptoms 
influenced by a variety of factors (Chapman, 2011; Wildgarrd et al, 2011; Herr, 2004). Thus, 
clinicians are beginning to expand the treatment of PTPS to include non-opioid based 
interventions and the impact of these new interventnions are just beginning to be known 
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(Keskinbora et al., 2007; Mattia et al., 2002; Lickiss, 2001).  A comprehensive approach to 
studying this phenomena which includes not only concurrent symptoms but also their influencing 
factors, has the potential to expand understanding of PTPS,  and inform the development of 
strategies to better  manage it. 
This study addresses the research priorities of the National Comprehensive Cancer and 
Oncology Nursing Society to develop an in-depth understanding of cancer-related symptoms and 
side effects, including causal pathways, patient outcomes, and nursing interventions to 
ameliorate symptoms (National Comprehensive Cancer Network, 2012; Eaton & Tipton, 2009). 
Optimally, findings of this study will assist clinicians to address three challenges: limited 
understanding of the patients’ full symptom experience, limited time to intervene in the clinical 
setting, and the need to identify innovative ways to improve the symptom experience. 
2.3 INNOVATION 
This study is thought to be the first to comprehensively examine the symptom experience 
following potentially curative surgical resection of lung cancer, including the experience of 
patients with and without PTPS. Since the 1990’s, few studies have examined the symptom 
experience of patients diagnosed with early stage lung cancer and hence, little is known about the 
types of symptoms patients experience, their influencing factors, or impact on performance after 
surgery.  
Tools to guide the assessment and management of symptoms after surgical treatment of 
lung cancer are lacking. The TOUS was used to guide this study with the promise of offering 
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clinical utility to reduce the impact of symptoms for persons who undergo surgery for lung 
cancer.  
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3.0  METHODS 
3.1 SETTING 
The study recruited patients over a 28 month period, between August 2010 and December 2012. 
Patients were recruited from the clinics of eight thoracic surgeons in one surgical practice. This 
surgical practice is affiliated with the University of Pittsburgh Medical Center (UPMC) Cancer 
Centers with locations at: Presbyterian Hospital, Hillman Cancer Center, Shadyside Hospital and 
Medical Center. 
3.2 SAMPLE 
A total of 1140 patients attended clinic and were screened, resulting in 112 potentially eligible 
subjects. Two patients were not enrolled due to refusal. Of the 110 patients who provided 
informed consent, 13 did not complete the study for the following reasons: 5 did not return 
instruments, 5 died, and 3 were no longer eligible due to new metastatic disease. The sample 
therefore consisted of 97 of 110 (88.1%) potential participants. All 97 were included in the PTPS 
Manuscript (Section 5). One subject of the 97, did not complete the symptoms instrument, and 
therefore was not included in the TOUS Manuscript (n=96) (Section 4).  
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3.3 RECRUITMENT 
Screening was based on the study’s inclusion and exclusion criteria. Prior to screening, all 
clinical staff were educated about the study and given screening cards to use as tools in 
introducing the study to potential participants. A member of the surgical team introduced the 
study to potential participants. If the patient agreed, the PI then approached the potential subject, 
confirmed that the potential subject met study inclusion criteria and, if eligible, obtained 
informed consent. During recruitment, the PI was present in the clinical suite and answered all 
study questions, from the staff, potential participants, and participants.  
Inclusion criteria. 1) managed surgically for Stage I, II, or IIIa lung cancer without 
evidence of metastasis (Siegel et al., 2011; American Lung Association, 2008; American College 
of Chest, 2007); 2) between two and 12 months post–surgery (conforms to definition of PTPS 
and other chronic symptoms) (International Association for the Study of Pain, 2011; Eaton & 
Tipton, 2009; Merskey & Bogduk, 1994; Merskey, 1986); 3) > 40 years of age (lung cancer was 
infrequent in those younger and if present likely atypical) (Howlader et al., 2010; American 
Lung Association, 2005; Parkin, Bray, Ferlay, & Pisani, 2005).  
Exclusion criteria. 1) any other cancer diagnosis or metastatic disease, (to avoid 
confounding symptomatology);  2) inability to speak, read, or understand English (questionnaires 
were in English); and 3) presence of comorbidities such as dementia, or memory loss (limited 
ability to participate as informant). 
After consent was obtained, participants were given the option of completing the 
instruments in the clinic suite or at home. If they chose the clinic suite, the PI verified the 
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instruments were completed. If completed at home, the participants were given a postage paid 
return envelope. The instruments were logged at the time of receipt. 
3.4 MEASURES 
 
3.4.1 Symptom Distress Scale (SDS) 
The SDS is a 13-item, self-report instrument designed to assess the level of distress associated 
with 11 cancer related symptoms e.g. fatigue, pain, insomnia, cough, breathing using a Likert-
type scale (one, least distress to five, most distress) (McCorkle, Cooley, & Shea, 1998; 
McCorkel & Young 1979). Ratings are summed to achieve a total symptom score ranging from 
13 to 65; total scores of 25 to 32 indicate moderate distress and scores ≥ 33 indicate severe 
distress (McCorkle et al., 1998; Holmes, 1989).  
In prior testing, the SDS was found to be internally consistent, with Cronbach's alpha 
coefficients ranging from 0.82 to 0.97 in populations including lung, breast, and other cancer 
patients (Chen, Lakshminarayanan, & Revicki, 2009; McCorkle et al., 1998; Holmes, 1989; 
McCorkel & Young 1979; Cronbach, 1951). The SDS was found to have acceptable construct 
validity based on the inverse relationship (r = -.58) found between the SDS and the Karnofsky 
Performance Status Scale (Sarna & Brecht 1997). The SDS was deemed internally consistent in 
this sample (Cronbach, 1951) with a Cronbach’s alpha of .852.  
27 
 
3.4.2 McGill Pain Questionnaire (MPQ) 
The MPQ is a self-report instrument that measures pain intensity, quality, and distress using 80 
descriptors in 21 pain categories (McGill, 2009; Wright, Asmudson, & McCreary, 2001). This 
instrument also includes a single pain intensity score, ranging from zero (none) to ten (severe) 
and a full body (front and back) figure on which respondents are asked to identify their pain and 
incisional sites by marking the specific body locations on this figure (McGill, 2009). Because 
prior studies of patients after chest surgery noted that, not just the surgical area, but also chest 
tube and drain sites were areas of pain, the instructions were modified to request that patients 
mark and rate their postsurgical pain at three locations: incision, drain, and chest tube sites. For 
this study an overall pain score was calculated based upon the incision pain score. 
In prior testing, the MPQ was found to be internally consistent, with Cronbach's alpha 
coefficients ranging between 0.74–0.87 (McGill, 2009; Ljunggren, Strand, & Johnsen, 2007; 
Jensen, 2003; Wright et al., 2001; Cronbach, 1951). The McGill was considered a valid measure 
of pain based upon Spearman rank (ρ) correlations  
3.4.3 Neuropathic Symptom Questionnaire (NSQ) 
Mid-way during the study the PI realized that patients were complaining of several sensations 
(numbness and tingling) that were not included in the SDS or MPQ. After reviewing several pre-
existing neuropathic pain instruments, none were deemed appropriate. The painDETECT 
(Freynhagen, Baron, Gockel, & Tolle, 2006), included items that overlapped with the McGill 
Pain Questionanire; the Neuropathic Pain Scale (Backonja & Krause, 2003) focused on pain and 
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included limited neuropathic descriptors that our participants reported such as numbness and 
tingling; other scales [LEEDS Assessment of Neuropathic symptoms, and the Neuropathic Pain 
Diagnostic Questionnaire (DN4)] focused on neuropathy and require a physical exam that 
includes a number of tests that entail testing that required specialized testing not judged feasible 
for this study. (Mongardon et al., 2011; Krause & Backonja, 2003; Snaith & Zigmond, 1994).  
Therefore, the NSQ, a self-report instrument was developed by the PI to identify the 
intensity of neuropathic pain based upon six descriptors at the surgical site: discomfort, tingling 
pain, numbness, increased sensation due to touch, increased sensation due to movement, and 
discomfort affecting daily activities. Patients were asked to rate each item using a 0-10 visual 
analog scale (VAS) with anchors established previously (Backonja & Krause, 2003). Using a 
VAS scale with anchors, 0 indicated no neuropathic sensation and ten the worst neuropathic 
sensation possible. Since the NSQ was introduced after half of the sample had been recruited, 
data for the NSQ were available for only 47 patients. Validity and reliability of the NSQ were 
not determined.  
3.4.4 Health History Survey (HHS) 
The HHS is a 20-item self-report instrument that was designed by the investigator to assess 
patients’ sociodemographic and medical characteristics. Selected items included age, smoking 
history (pack years), gender, race, and ethnicity. Medical information, provided by the 
participant and verified by the medical record included: location and tumor type 
(adenocarcinoma – other), cancer stage (Stage I – Stage II or IIIa), surgical approach 
(thoracotomy-thoracoscopic),  surgical procedure (lobectomy-other) time since surgery (2 to 6 – 
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7 to 12 months) and tumor location by lobe (right upper lobe – others). Validity and reliability of 
the HHS were not determined.  
3.4.5 Charlson Comorbidity Index (CCI) 
The 16-item version of the CCI (Heller, Ahern, Pringle, & Brown, 2009) that was modified to 
eliminate overlapping items included in the original 19-item scale (Charlson, et al 1987) to 
reflect the extent of morbidity associated with chronic illness, including those with lung cancer 
(Heller et al., 2007; Wang et al., 2007; Hall, Ramachandran, Narayan, Jani, & Vijayakumar, 
2004). Scores were calculated by applying a weighted value to each comorbid condition 
documented in the medical record for a possible range of scores from 0 to 24 with higher scores 
indicating higher comorbidity burden. Content validity for the CCI was strong for detecting 
comorbid illnesses in a sample of 30,535 U.S. elderly patients (Heller et al., 2007). CCI scores > 
5 have been found to predict 1-year mortality for patients with a range of conditions, e.g. heart 
disease, AIDS, lung cancer (Charlson, et al., 1987); 
In the present study, each condition was verified with the medical record and coded as 
absent or present (Hall et al., 2006). Per scoring guidelines (Wang et al., 2007),  a weight of one 
was assigned for coronary heart disease, myocardial infarction, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, 
connective tissue disease, peptic ulcer disease, mild liver disease, and diabetes. A weight of two 
was assigned for hemiplegia, moderate/severe renal disease, and moderate /severe diabetes with 
end organ damage. A weight of three was assigned for liver disease and a weight of six was 
assigned for participants with AIDS However, no participant in this study had hemiplegia or 
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items assigned weights greater than or equal to two and participants were excluded for dementia. 
The result was that only twelve of the 16 potential comorbid conditions were present in this 
population.  
3.4.6 Hospital Anxiety and Depression Scale (HADS) 
The HADS is a 14-item questionnaire, designed to screen for mood disorders (Snaith, 2003). The 
HADS includes an anxiety and depression subscale; each subscale contains seven Likert-
response items scored zero to three for a possible subscale range of 0-21 (Snaith, 2003). Based 
on prior studies, scores < seven are considered normal; scores 8-10 are suggestive of a mood 
disorder; scores ≥ 11 indicate probable presence of a mood disorder (Snaith, 2003; Zigmong & 
Snaith 1983).  
The HADs has been used widely (Bjelland et al 2002; Zigmond, & Snaith, 1983) and has 
been shown to be internally consistent with Cronbach’s alpha coefficients  of .81, .90, and .87 for 
the anxiety, depression and total HADS scores, respectively (Zigmond and Snaith 1983). A 
review of studies that employed the HADS reaffirmed the construct validity of the HADs 
(Bjellend, Dahl, Haug, & Neckelmann, 2002; Snaith, & Zigmond, 1994). In the present study, 
The HADS was deemed internally consistent in this sample with a Cronbach’s alpha of .89, .88, 
and .93, for anxiety, depression and total HADS scores, respectively.  
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3.4.7 Functional Assessment of Cancer Therapy-Lung (FACT-L)  
The FACT-L is a 44-item, self-report instrument with 5 subscales designed to measure five 
dimensions of quality of life (e.g. physical, social, functional, emotional) and a cumulative total 
score (Myers, 2009; Cella et al., 2002). The 44 Likert response items were scored using the 
established Administration and Scoring Guidelines (Cella et al., 2002). The sub-scores were 
summed and averaged to obtain a total score; higher scores indicate higher levels of functional 
performance. Likert scale (zero equals not at all, to a four which equals very much) and is 
considered a QOL measure (Cella et al., 1995). 
             The FACT-L was developed as a revised version of the FACT-G, with additional lung 
cancer focused questions. Cella (1995), validated internal consistency between the historical 
FACT-G and the FACT-L, by administering the FACT-L lung questions with the FACT-G 
questionnaire to 116 patients with lung cancer; the internal consistency (Cronbach’s alpha) was 
0.68.  Soni and colleagues (2002), verified content validity using a comprehensive literature 
review and deemed the FACT-L to be one of three most comprehensive lung cancer-specific 
QOL measures. In more recent studies of patients with lung cancer, the FACT-L was found to be 
reliable with alpha coefficients  >  .81 for the total and each of the subscale scores (Browning, 
Ferketich, Otterson, Reynolds, & Wewers, 2009); strong criterion validity was found between 
the FACT-L and the Lung Cancer Symptom Scale (Browning et al., 2011). In this sample 
Cronbach’s alpha for the total FACT-L and its subscales ranged between .57 and .82.  
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3.5 HUMAN SUBJECTS PROTECTION 
3.5.1 Data Sources 
Data sources included self-report questionnaires and abstraction of data from medical records. 
Screening was based on the study’s inclusion and exclusion criteria (Section 3.2).  
3.5.2 Potential Risks and Protection Against Risks  
The major risks were fatigue, distress from recall of the surgical experience, or breach of 
confidentiality. If patients complained of fatigue or distress, they were given an opportunity to 
rest and continue participation later. To reduce the likelihood of a breach of confidentiality, 
questionnaires were assigned a code number and stored in a locked file cabinet separate from the 
file containing identifiable information of participants.  
Two study instruments measured symptoms that could reflect a level of distress requiring 
notification of clinic staff.  For the SDS, clinic staff was notified of scores ≥ 33 (severe distress). 
Per protocol, the clinical staff were notified within 24 hours of the high SDS scores for 10 
participants; and the staff confirmed that all participants were currently receiving treatment for 
conditions related to their scores. For the HADS, scores ≥ 11 (probable presence of mood 
disorder), were reported to clinic staff within 24 hours.  Of the 97 patients enrolled in this study, 
the clinical staff were notified of high HADS scores for two participants who confirmed that all 
participants were currently receiving treatment for these conditions.  
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3.5.3 Informed Consent 
Participants were informed about the study by the surgical team either during a clinic visit (using 
an IRB clinician recruitment script) or by an IRB formatted letter mailed to their homes. If 
interested in participating, both methods informed potential participants how they could contact 
the PI. This contact was typically done by phone or during the participant’s next clinic visit. 
Those participants who chose to contact the PI by phone or in the office were screened using an 
IRB-approved script. If participants elected not to participate or were not eligible, all data 
obtained from the screening interview was destroyed. Participants were informed that their 
participation in this study was completely voluntary, they could refuse to take part in it or 
withdraw at any time, even after signing informed consent and their decision to not participate in 
the study did not affect their relationship with or the care received from the UPMC Cancer 
Centers or UPMC.  
3.5.4 Potential Benefits 
Participants were not likely to experience any direct benefit from this study, although some 
found the opportunity to share their experiences of dealing with lung cancer gratifying. It was 
hoped that study data would provide findings that would be used to improve care for future 
patients.  
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3.5.5 Importance of Knowledge to be Gained 
It was hoped that, the knowledge gained from this study will improve outcomes of patients 
diagnosed with early stage lung cancer by providing information that was disseminated through 
publications and presentations and used to design future interventions.  
3.5.6 Data Safety Monitoring Plan 
Data and safety monitoring were conducted during monthly meetings with the Sponsor and Co –
Sponsor during which data acquisition, management and any adverse events arising from the 
study were reviewed. Study procedures required that evidence of these reviews be provided to 
the IRB at the time of the yearly renewal.  No unanticipated adverse events occurred.  
3.5.7 Inclusion of Woman, Minorities, and Children 
At the time of the study, patient demographic composition at the UPMC Cancer Center were 
49% female; 1% Hispanic, 99% Non-Hispanic with a Non-Hispanic population composition of: 
0% American Indian/Alaskan Native and Native Hawaiian/Pacific Islander, 5% Asian, 20% 
African American and 75% Caucasian.  
Based on American Cancer Society 2008 statistics, the annual incidence of lung cancer 
per 100,000 people in minorities was 154.1 for blacks, 140.9 for whites, 68.9 for American 
Indians/Alaska Natives (AI/ANs), 122.6 for Asian/Pacific Islanders, and 22.3 for Hispanics 
(American Lung Association, 2008). Slightly more men than women were diagnosed with lung 
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cancer; however the incidence in men has been relatively stable whereas the incidence in women 
steadily increased until 2010 (American Cancer Society, 2014; American Lung Association, 
2008).  
The present study incorporated several measures to ensure ability to meet minority and 
gender recruitment goals. Dr. Rosenzweig (Committee Member) had been conducting research 
involving African American women with breast cancer. She and her team, which included 
several minority participants, provided advisement on ways to insure that the final sample 
reached the desired minority and gender participation goals, including publicizing the study 
through literature placed in the clinic and creating an atmosphere that encouraged participation. 
Gender and race of participants enrolled in this study were consistent with UPMC-wide patient 
demographics and slightly lower than the national averages.  
3.6 METHODS SPECIFIC TO STUDY I: A DESCRIPTION OF THE SYMPTOM 
EXPERIENCE AFTER SURGERY FOR LUNG CANCER BASED ON THE THEORY 
OF UNPLEASANT SYMPTOMS (TOUS) 
3.6.1 Purpose 
The purposes of Study I: TOUS (Chapter 4) were: to describe the symptom experience of lung 
cancer patients within their first year after thoracic surgery and to determine the clinical utility of 
the TOUS for monitoring and managing symptom distress. The specific aims of the Study I were 
to: describe the symptoms experienced by patients in the first year following lung cancer 
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surgery, determine the associations between  physiologic, psychologic and situational factors that 
influence patients’ symptom(s), and determine the associations between symptom(s) on patients’ 
performance.  
3.6.2 Design 
A cross-sectional, correlational design was used to describe the symptom experience and 
examine the relationships supported by the TOUS.  
3.6.3 Data Analysis 
Using SPSS Version 21 (2013, Armonk, New York), data were inspected for accuracy, missing 
values, and normality of distributions (Pallant, 2007; Tabachnick & Fidell, 2007). Data were 
inspected for accuracy, missing values, and normality of distributions (Pallant, 2007; Tabachnick 
& Fidell, 2007). Descriptive statistics were used to calculate percentages, frequencies, means, 
and standard deviations. When indicated, due to distribution of the data, variables were 
dichotomized. Scores obtained from the instruments used for this study were not normally 
distributed. Therefore, Spearman’s rho (p <.05), was used to determine correlations between  
measures of symptom distress, influencing factors, and performance. The anxiety and depression 
subscales were highly correlated (rho = .752, p< .01); therefore, the HADS total score was used 
in the analysis. Statistical significance was set at p ≤ 0.05 for all variables.  
 
37 
 
3.7 METHODS SPECIFIC TO STUDY II: POST THORACOTOMY PAIN 
SYNDROME (PTPS) FOLLOWING SURGERY FOR LUNG CANCER: PREVALENCE, 
CHARACTERISTICS AND IMPACT ON QUALITY OF LIFE   
3.7.1 Purpose 
The purpose of Study II (PTPS) (Chapter 5) was to compare the prevalence, characteristics, 
symptom experience, and impact of symptoms on quality of life in patients with and without 
PTPS. 
3.7.2 Design 
A between group comparison was used to describe the symptom experience of patients with and 
without PTPS.  
3.7.3 Data Analysis 
Using SPSS Version 21 (2013, Armonk, New York), data were inspected for accuracy, missing 
values, and normality of distributions and proportions (Pallant, 2007; Tabachnick & Fidell, 
2007). Chi-Square or Fisher’s exact test were used to determine differences between participants 
with and without PTPS (Pallant, 2007; Tabachnick & Fidell, 2007). Mann Whitney test was used 
to test for statistical significance between groups not normally distributed (Pallant, 2007; 
Tabachnick & Fidell, 2007). When significant differences were found, post-hoc comparisons 
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(Kruskal-Wallis) were performed to detect the point of difference (Tabachnick & Fidell, 2007). 
Significance was set at alpha ≤ 0.05.  
3.8 SUMMARY OF FINDINGS  
3.8.1 Study I: TOUS 
There were six major findings in this study: 1) patients with no evidence of metastatic disease 2-
12 months following surgery for lung cancer reported frequent symptoms; 2) although symptoms 
were frequent and often concurrent, most symptoms were associated with mild to moderate 
distress; 3) influencing factors were predominantly psychologic; 4) younger and earlier stage 
lung cancer patients reported more symptom distress; 5) greater symptom distress was associated 
with a greater impact on performance; and 6) greater psychological distress was associated with 
increased symptom distress and lower performance. 
3.8.2 Study II: PTPS  
The major findings in this study were: 1) patients who underwent a thoracotomy or 
thoracoscopic procedure using current surgical techniques were equally likely to report 
symptoms consistent with PTPS; 2) patients who experienced PTPS had discomfort at varied 
locations (incision, shoulder, chest tube and drain insertion sites), 3) Younger patients were more 
likely to report PTPS; 4)PTPS discomfort manifested as pain only, neuropathic symptoms only, 
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or as combination of both; and 5) symptom distress and quality of life differed significantly 
between patients with and without PTPS.  
  
3.8.3 Plan for Publication of Findings  
A summary of these findings are presented in the format of two manuscripts to be submitted for 
publication; Study I: TOUS in Chapter 4 and Study II: PTPS in Chapter 5. 
3.9 SUMMARY OF GLOBAL IMPLICATIONS  
3.9.1 Study I: TOUS 
In 2008, the World Health Organization (WHO) recognized cancer as a leading cause of death 
with an estimated 7.6 million deaths worldwide, a number that is expected to increase to over 13 
million deaths in 2030. Lung cancer was noted as a common cause of cancer death, accounting 
for 1.37 million (71%) of these deaths (Globocan, 2010). Hence, management of the care of 
patients who acquire lung cancer is an important aspect of nursing practice and, in particular, the 
practice of clinicians whose practice focuses on oncology.  These findings can be used globally 
to improve the care of patients diagnosed with lung cancer. In particular, this study provides 
support for the TOUS as a conceptual framework with clinical utility assisting oncology 
clinicians in both explaining and identifying: the interaction of symptoms, influencing factors 
and their impact on performance in patient with cancer.  
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3.9.2 STUDY II. PTPS  
In 2008, the WHO and the International Agency for Research on Cancer (IARC) collaborated 
with worldwide partners in the development and implementation of a Cancer Control: 
Knowledge into Action Plan designed to increase palliative care interventions for more effective 
management of symptoms resulting from cancer (World Health Organization, 2008). Pain and, in 
particular PTPS, is a concern for those involved in cancer care (Chapman, 2011; Pituskin et al., 
2010; Montazeri et al., 1998). Findings of this study enhance understanding of symptoms 
associated with PTPS and, in particular, its neuropathic origins.  
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4.0  STUDY I: A DESCRIPTION OF THE SYMPTOM EXPERIENCE AFTER 
SURGERY FOR LUNG CANCER BASED ON THE THEORY OF UNPLEASANT 
SYMPTOMS (TOUS) 
Abstract 
Purposes:  Although therapies have increased survival rates for lung cancer, symptom 
assessment and management of symptoms after lung cancer surgery remain a significant 
problem. The purpose of this study were to describe the symptom experience of lung cancer 
patients within their first year after thoracic surgery using the concepts and relationships of the 
Theory of Unpleasant Symptoms (TOUS) and to determine whether the TOUS has clinical utility 
for the monitoring and managing of symptoms.  
Design: Descriptive, cross sectional, correlational study 
Setting: Surgical oncology clinics of a large, academic medical center in the Mid-Atlantic 
Region of the United States 
Sample: Convenience sample of 96 patients with no evidence of metastases who were between 
two months and 12 months after surgery for Stage I, II, or IIIa lung cancer  
42 
 
Methods: Patients who met eligibility criteria completed six self-report instruments during a 
regularly scheduled clinic visit. Data regarding clinical characteristics and comorbidities were 
abstracted from the medical record. Descriptive statistics were used to summarize results. Due to 
non-normality, Spearman’s rho (p ≤ .05) was used to determine correlations between symptom 
distress, influencing factors, and performance.   
Main Research Variables and Measures: The TOUS includes three major concepts: symptoms, 
influencing factors (physiologic, psychologic, or situational), and performance. The Symptom 
Distress Scale (SDS) was used to measure symptom distress. Physiologic factors (age, gender, 
race, cancer stage, comorbidities and surgical approach) were measured using items of the 
Health History Survey (HHS) and the Charlson Comorbidity Index (CCI). Psychologic factors 
were measured using the Hospital Anxiety and Depression Scale (HADS) which includes 
subscales for anxiety and depression. Situational factors (educational level, marital status, and 
residential area) were measured using items of the Health History Survey (HHS). The Functional 
Well-Being Subscale of the Functional Assessment of Cancer Therapy-Lung (FACT-L) was 
used to measure functional performance. 
 
Findings: The mean age of the sample was 67 years. Mean time since surgery was 6 months (SD 
= 2.9). The majority were white (92%) and married or with a steady partner (65%). On average, 
patients had 5.2 comorbid conditions (range 2-10). The median number of symptoms was 3, with 
91% of patients reporting the presence of 2 or more concurrent symptoms. The majority of 
patients (97%) reported some level of symptom distress. Statistically significant negative 
correlations were found between age (rho = -.279, p <.01) and cancer stage (rho = -.228, p< .05) 
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and higher levels of symptom distress; those younger in age and later in stage reported more 
symptom distress. Statistically significant negative correlations were also found between level of 
symptom distress and performance (FACT-L functional subscale) (rho =-.684, p <.01); those 
with more symptom distress had less functional performance. Statistically significant positive 
correlations were found between psychologic factors (total HADS score) and level of symptom 
distress (rho =.763, p <.01) and poorer functional performance (rho = -676, p <.01). No 
additional physiologic factors (gender, surgical approach or CCI scores) or any of the situational 
factors (education, marital status, or place of residence) were significantly correlated with 
symptom distress.  
Conclusion: Patients with early-stage lung cancer and no evidence of metastasis reported a wide 
range of post-operative symptoms. The majority of these symptoms occurred concurrently and 
were, for some, associated with severe distress. Consistent with the TOUS, the extent of 
symptom distress was found to influence functional performance. Greater psychologic distress 
(anxiety and depressive symptoms) was associated with increased levels of symptom distress and 
poorer functional performance. Some, but not all, physiologic influencing factors were 
associated with higher levels of distress; no situational influencing factors were significantly 
associated with symptom distress.  
Implications for Nursing/Interpretation: The majority of patients reported multiple symptoms and 
some degree of symptom distress. Psychologic distress was found to be the strongest influence 
on level of symptom distress and reduced functional performance. A comprehensive approach to 
assessing and managing symptoms after surgery for lung cancer is needed. Oncology nurses can 
use the TOUS as a guide to assess an individual’s symptoms, the factors that may be influencing 
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symptom distress and the impact of symptoms on performance in order to tailor symptom 
management strategies to the individual’s experience.  
Knowledge Translation: The TOUS provides clinical utility for nurses, as it reinforces the need 
to assess the presence of symptoms, degree of distress associated with the symptoms, factors that 
influence these symptoms, and impact of symptoms on performance.   
4.1 INTRODUCTION 
Lung cancer claims more lives each year worldwide than colon, prostate, ovarian, lymph, and 
breast cancer combined (American Cancer Society, 2013).  Although new surgical techniques 
and combination therapies have increased survival rates (American Cancer Society, 2013), 
symptom assessment and management remain a significant problem (Gift, Jablonski, Stommel, 
& Given, 2004; Sarna et al., 2008). Up to 77% of patients report multiple concurrent symptoms 
(Cheng & Lee, 2011; Gift et al., 2004). Even long-term lung cancer survivors are known to 
experience substantial symptom burden and impaired QOL years after surgery (Yang et al, 
2012). Severe symptoms such as fatigue, dyspnea, cough, and pain often persist beyond the first 
two months post-operatively (Sarna et al., 2008). However, our understanding of the factors that 
influence symptoms after surgery for lung cancer and the impact of symptoms on performance is 
limited. Since the patients’ symptom experiences after lung cancer surgery is complex, a 
comprehensive assessment is important for monitoring and managing symptoms. 
The TOUS purports relationships between symptoms, influencing factors, and 
performance (Figure 3). Symptoms are considered “red flags” that indicate changes in the 
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patient’s normal functioning (Hegyvary, 1993), are multidimensional, and often occur 
concurrently (Lenz, Pugh, Milligan, Gift, & Suppe, 1997).  Influencing factors (physiologic, 
psychologic and situational) influence symptoms which, in turn, impact functional performance 
and account for the distress, reduced QOL and other negative consequences of the symptom 
experience. The TOUS captures the complexity of the symptom experience (Lenz et al., 1997), 
and therefore, may serve as a useful framework for monitoring and managing symptoms.  
        The purposes of this study were to use the TOUS to describe the symptom experience of 
lung cancer patients within their first year after thoracic surgery and determine if the TOUS has 
clinical utility for monitoring and managing symptom distress. 
4.2 METHODS 
4.2.1 Design 
A cross-sectional, correlational design was used to describe the symptom experience based upon 
the relationships supported in the TOUS. The study was approved by the Institutional Review 
Board, and patients provided written informed consent.  
4.2.2 Sample Screening and Recruitment 
Convenience sampling was used to recruit a cross-sectional cohort of patients treated by eight 
surgeons in three of the 14 university-based surgical oncology clinics of a large academic 
medical system between August 2010 and December 2012. Inclusion criteria were: 1) managed 
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surgically for Stage I, II, or IIIa lung cancer without evidence of metastasis (American College 
of Chest, 2007); 2) between two and 12 months post surgery for lung cancer (conforms to 
definition of chronic post-thoracotomy pain syndrome) (International Association for the Study 
of Pain, 2011); and 3) > 40 and < 86 years of age (lung cancer is infrequent at a younger age, and 
if present, likely atypical; older individuals are unlikely to be surgical candidates) (American 
Lung Association, 2008; Howlader et al., 2010). Exclusion criteria were: 1) any other cancer 
diagnosis or metastatic disease (to avoid confounding symptoms); 2) inability to speak, read, or 
understand English (instruments were in English); and 3) dementia or memory loss (limited 
ability to participate as informant). 
To facilitate recruitment, clinic staff were educated about the study and given cards 
describing the inclusion and exclusion criteria to aid in identifying potential study participants. 
Clinic staff prescreened potential participants for eligibility, introduced the study, and referred 
interested patients to the principal investigator, who reconfirmed eligibility, obtained written 
informed consent and collected data.  
4.2.3 Measures by Concepts of the TOUS 
Symptoms  
Symptoms were measured using the Symptom Distress Scale (SDS). The SDS is a 13-item, self-
report instrument for patients to rate their distress due to cancer-related symptoms using Likert-
scale responses (1 = No distress; 5 = Most distress). The total SDS distress score is calculated by 
summing distress ratings for all symptoms; possible scores range from 13 (no symptom distress) 
to 65 (highest level of distress) (McCorkle, Cooley, & Shea, 1998). Based on prior breast cancer 
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studies, total SDS scores of 25 to 32 represent moderate levels of distress, and scores greater than 
32 represent severe distress (McCorkle et al., 1998). In addition to determining the overall level 
of symptom distress and distress for each symptom, the SDS was used to describe the number, 
type and presence of concurrent symptoms. The SDS has established reliability with Cronbach's 
alpha coefficients ranging from .82 to .97 in cancer populations, including persons with lung 
cancer, (McCorkle et al., 1998) and .85 in this sample. The SDS was found to have acceptable 
construct validity based on the inverse relationship found between the SDS and the Karnofsky 
Performance Status Scale (Sarna & Brecht 1997). 
Physiologic Influencing Factors 
The Health History Survey (HHS), an investigator-designed instrument, was used to 
assess the socio-demographic and clinical characteristics of the sample including age, gender, 
race, cancer stage and surgical approach. The 16-item version of the Charlson Comorbidity 
Index (CCI) (Heller, Ahern, Pringle, & Brown, 2009) was used to identify the number and 
severity of comorbidities. Scores were calculated by applying a weighted value to each comorbid 
condition documented in the medical record for a possible range of scores from 0 to 24 (Heller, 
Ahern, Pringle, & Brown, 2009) Higher scores indicate higher comorbidity burden. The original 
19-item version CCI has well established validity with higher scores associated with increased 
mortality (X2 = 165; p <.0001) (Charlson, et al 1987). Modification from the 19-item version to 
the 16-item version was made to eliminate overlapping items (Heller et al., 2009). 
Psychologic Influencing Factors 
The Hospital Anxiety and Depression Scale (HADS), a 14-item, self-report instrument, 
was administered to assess the presence of distressing mood (Snaith, 2003). The HADS includes 
an anxiety and depression subscale; each subscale includes seven Likert-scale items scored from 
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0 to 3, with some scores reversed so that higher scores indicate worse mood (Snaith, 2003). 
Items are summed for a possible range of 0-42 for the total HADS score and 0-21 for each 
subscale.  Based on previously established thresholds for psychologic distress (Snaith, 2003), 
subscale scores between 0 and 7 are considered normal; subscale scores between 8 and 10 are 
suggestive of a mood disorder; and subscale scores ≥ 11 indicate the probable presence of a 
mood disorder. Initially developed in 1983, the HADs was shown to be internally consistent and 
reliable with Cronbach’s alpha coefficients  of .81, .90, and .87 for the anxiety, depression and 
total HADS scores, respectively (Zigmond and Snaith 1983)  The HADS has since been used in 
over 740 studies (Bjelland et al 2002). A review of these studies reaffirmed the construct validity 
of the HADs. In the present study, Cronbach’s alpha coefficients were .89 .88, and .93, for 
anxiety, depression and total HADS scores, respectively.  
Situational Influencing Factors 
 
Additional items of the Health History Survey (HHS) were used to assess situational 
factors. These were defined as the highest level of education, marital status and residential area 
(rural or urban).  
Performance 
The FACT-L includes five subscales measuring physical, social, emotional and 
functional well-being and an additional subscale for lung. Higher scores indicate a more positive 
assessment of quality of life. The TOUS model measures performance, rather than quality of life 
and, recently, researchers have noted that functional status is a more appropriate measure of 
performance, rather than QOL (Cheng & Lee, 2011). Therefore, the 7-item Functional Well-
Being subscale of the FACT-L (Cella et al., 2002) was used to measure physical performance. 
Higher scores indicated higher levels of functional performance.  
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In studies of patients with lung cancer, the FACT-L was found to be reliable with alpha 
coefficients  >  .81 for the total and each of the subscale scores (Browning, Ferketich, Otterson, 
Reynolds, & Wewers, 2009); strong criterion validity was found between the FACT-L and the 
Lung Cancer Symptom Scale (Browning et al., 2011). Cronbach’s alpha for the functional 
subscale in this sample was .90.  
4.2.4 Data Analysis 
Analyses were conducted using SPSS Version 21 (2013, Armonk, New York). Data were 
inspected for accuracy, missing values, and normality of distributions (Pallant, 2007; Tabachnick 
& Fidell, 2007). Descriptive statistics were used to calculate percentages, frequencies, means, 
and standard deviations. Due to a disproportionate number of cases in the original groupings, 
both physiological (gender, cancer stage, surgical approach) and situational influencing factors 
(education, marital status, and residential area) were dichotomized. Due to limited variation in 
the sample, race was not included in the final analysis. None of the continuous scores (CCI, SDS, 
HADS, FACT-L) were normally distributed, therefore, Spearman’s rho (p <.05), was used to 
determine correlations between measures of symptom distress, influencing factors, and 
performance. The anxiety and depression subscales were highly correlated (rho = .752, p< .01); 
therefore, the HADS total score was used in the analysis.  
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4.3 RESULTS 
Of the 112 patients deemed eligible, 110 agreed to participate, yielding a 98% acceptance rate. 
Fourteen subjects were lost to attrition, resulting in final sample of 96 subjects (Figure 4) .  
 
1140 potential participants
August 2010 – December 2012
1028  ineligible  because: 
• Advance Stage/Metastatic n = 
901
• <2 months n = 23
• >12 months n = 99
• Age 40< >85 n = 3
• Dementia/Memory Loss n = 2
13 discontinued participation
• No reply n= 5 
• Died post-consent n=5 
• Chemotherapy n= 3
2 refused 
110 consented
112 eligible 
Study II: PTPS 
97 completed the study
Study I: TOUS 
96 completed the study
1 not included
• No SDS nor HADS 
 
Figure 4.  Flowchart of study recruitment and retention 
 
4.3.1 Sample Characteristics 
Characterstics of the sample, including scores on the instruments, are presented in Table 1 and 
discussed below, according to the concepts of the TOUS.  
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Table 1. Characteristics of the TOUS concepts (n=96) 
  
N 
 
% 
 
Mean 
 
SD 
 
Range 
Symptoms      
        Symptom Distress Scale (Total Score)   22.4 7.4 (13-49) 
Physiologic Influencing Factors      
       Time since surgery, months  
       Age, years  
  6.0 
67.2 
2.9 
9.7 
(2-12) 
(45-84) 
       Gender, Male 46 47.9    
       Race, White   88 91.7    
       Cancer Stage 
   Stage I 
   Stage II 
               Stage IIIa 
 
53 
31 
12 
 
55.2 
32.3 
12.5 
   
       Surgical Approach 
               Thoracotomy 
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53.1 
   
               Thorascopic 45 46.9    
       Charlson Comorbidity Index   5.2 1.5 (3-10) 
Psychologic Influencing Factor  
       Hospital Anxiety and Depression Scale 
     
               Anxiety Subscale-score   4.3 3.9 (0-15) 
               Depression Subscale-score    3.6 3.6 (0-16) 
               Total HADS Score    7.9 7.1 (0-26) 
Situational Influencing Factors      
      Highest Level of Education 
  Elementary 
  High School/GED 
  Technical School/Some College 
              College Graduate 
 
9 
39 
28 
20 
 
9.3 
40.6 
29.2 
20.8 
   
     Marital Status 
  Divorced 
  Single 
  Widowed 
              Married or in a steady partnership 
 
16 
4 
14 
62 
 
16.7 
4.2 
14.6 
64.6 
   
      Residential Area 
              Rural 
              Urban 
 
50 
46 
 
52.1 
47.9 
   
Performance a      
        FACT-L  
        Functional Performance Subscale-score 
   
20.3 
 
7.0 
 
(0-28) 
a n=95 
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Symptoms  
Total SDS scores ranged from 13 to 49 with a mean (SD) of 22.4 (7.4) (Table 1). The 
distribution of total SDS scores with the line of threshold ≥ 33 indicating severe distress 
(McCorkle et al., 1998; Holmes, 1989) are presented in Figure 5.The number of patients 
endorsing each symptom and the level of reported distress per symptom is shown in Figure 6.  
The number of symptoms reported per patient ranged from 0 - 13 (mode = 3). The majority 
(91%) reported the presence of concurrent symptoms (> 2 symptoms) (Figures 5 & 6).  
 
 
Figure 5. Distribution of SDS total scores 
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Figure 6. Symptom distress ratings 
 
Physiologic Influencing Factors 
Age ranged from 45 to 84 with a mean of 67 years (Table 1). The majority was white 
(92%). Approximately half were female (52%), underwent a thoracotomy (53%), and had Stage 
1 lung cancer (55%). The number of comorbid conditions ranged from 3-10 with a mean CCI 
score of 5.2 (1.5), median of 5. 
Psychologic Influencing Factors  
The total HADS score ranged from 0 to 26 with a mean of 7.9 (7.1). Mean anxiety and 
depression subscale scores were 4.3 and 3.6, respectively. Six patients (6.2%) reported sub-
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scores > 11 for either anxiety or depression, the threshold for a reportable mood disorder. These 
findings were reported to the clinical staff and all patients were found to be currently receiving 
treatment for their psychologic distress.  
Situational Influencing Factors  
The majority of the sample was married or with a steady partner (62%). Nearly half were 
educated beyond high school (49%) and more than half resided in a rural area (52%).  
Performance  
The mean FACT-L functional subscale score for the sample was 20.3 (7.0), with a 
median of 22. Scores ranged from 0 to 28.  
4.3.2 Correlational Analysis 
The correlation coefficients (Spearman’s rho) between symptoms, influencing factors and 
performance are shown in Table 2. Statistically significant negative correlations were found 
between symptom distress and two physiologic influencing factors (age and cancer stage I) (rho 
= -.279, p<.01 and rho = -.228, p<.01, respectively), and between level of symptom distress and 
performance (rho = -.684, p<.01). Statistically significant positive correlations were found 
between symptom distress and psychologic influencing factors (total HADS score) and level of 
symptom distress (rho=.763, p<.01). 
 Two physiologic influencing factors, age and gender, demonstrated significant negative 
correlations with the psychologic influencing factors (total HADS score), (rho = -.308, p<.01 and 
rho = -.263, p<.01, respectively). Cancer stage I was positively correlated with performance (rho 
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=.205, p <.05). In addition, the psychologic influencing factors (total HADS score) was 
negatively correlated with performance (rho = -.676, p<.01).  No other physiologic influencing 
factors (gender, surgical approach, CCI scores) or situational influencing factors (education, 
marital status, place of residence) were significantly correlated with symptom distress, 
influencing factors or performance. 
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Table 2. Correlational comparisons (n=96) 
  
Symptoms 
 
 
Influencing 
(Physiologic) 
 
Factors 
 
  
 
 
 
(Psychologic) 
 
 
(Situational) 
   
Performance 
 SDS 
Total 
Score 
Age 
 
Gender 
Male 
Cancer  
Stage I 
CCI 
Total 
 Score 
HADS 
Total 
Score 
Education 
College 
 
Marital status: 
Married/ 
steady 
partnership 
Residence 
Urban 
 
FACT-L a 
Functional 
Sub-Score 
Symptoms 
SDS 
Total Score 
 
- 
 
-.279** 
 
-.194 
 
-.228* 
 
.170 
 
.763** 
 
-.093 
 
-.127 
 
.034 
 
-.684** 
Influencing 
Factors 
(Physiologic) 
Age 
 
 
 
  
 
.094 
 
 
-.062 
 
 
.097 
 
 
-.308** 
 
 
-.070 
 
 
-.042 
 
 
-.036 
 
 
.130 
Gender: Male    -089. -.196 -.263** .237* .193 -.012 .025 
Cancer Stage: I     -.041 -.112 .137 .028 .019 .205* 
CCI Total Score      .135 -.146 -.133 -.002 -.109 
Influencing 
Factors 
(Psychologic) 
HADS 
       
 
-.179 
 
 
-.160 
 
 
.022 
 
 
-.676** 
Influencing 
Factors 
(Situational) 
Education: College 
 
 
 
 
 
 
     
 
 
 
 
-.008 
 
 
.010 
 
 
.130 
Marital Status: 
married/ steady 
partnership 
        .092 .007 
Residence: Urban          -.163 
Performance 
FACT-L a 
Functional Sub-
Score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 
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4.4 DISCUSSION 
There were six major findings in this study: 1) patients with no evidence of metastatic disease 2-12 
months following surgery for lung cancer reported frequent symptoms; 2) although symptoms were 
frequent and often concurrent, most were associated with mild to moderate distress; 3) influencing 
factors were predominately psychologic; 4) younger and earlier stage lung cancer patients reported 
more symptom distress; 5) greater symptom distress was associated with a greater impact on 
performance; and 6) greater psychological distress was associated with increased symptom distress and 
lower performance.  
4.4.1 Symptoms 
In the present study, the majority (96%) of patients with no evidence of metastatic disease following 
lung cancer surgery reported some level of symptom distress. In addition, most (91%) patients reported 
the presence of concurrent symptoms (> 2 symptoms), with 14 (14.6%) patients reporting 3 concurrent 
symptoms and 12 (12.4%) patients reporting 5-7 concurrent symptoms. Although most scores reflected 
low to moderate distress, 10 patients (10%) presented with scores reflecting severe distress. Our 
findings support the need to comprehensively assess patients for symptom distress following the 
diagnosis of lung cancer, including those with early stage disease that who underwent surgery and those 
who are beyond the immediate postsurgical period.    
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Findings from the present study support that patients diagnosed with lung cancer experience 
multiple and common symptoms, regardless of the stage of the disease. The most frequently reported 
symptoms in this sample were fatigue (76%), cough (62%), breathing (54%) and pain (36%) were 
consistent with those previously reported (Gift, Jablonski, Stommel, & Given, 2004). Sarna et al., 
(2008) , reported the most commonly occurring symptoms as fatigue (57%), dyspnea (49%), cough 
(29%), and pain (20%), measured by the Lung Cancer Symptom Scale (Sarna et. al., 2008).  Both 
studies report symptoms similar to those reported by patients in the present study. Level of distress was 
difficult to compare owing to difference in instruments. 
4.4.2 Influencing Factors 
Physiologic influencing factors examined in this study, such as sociodemographics indicated that our 
sample was comparable to other lung cancer populations with regard to age and gender. Younger 
patients reported greater symptom distress, a finding contrary to prior studies. Earlier research in 
patients with lung cancer indicated that age (older) may be related to the type of symptoms reported and 
the level of distress associated with these symptoms (Gift et al., 2004). Although the mean age of our 
patients was typical of those with this diagnosis, there was a large range (45-84) that included patients 
notably younger than typical for this diagnosis, a potential explanatory factor.  
 Psychologic influencing factors measured in our sample reflected lower levels of anxiety and 
depression compared to a prior study of patients treated surgically for Stage I, II, or IIIa lung cancer 
(Sarna et al, 2010) but comparable to levels of distress among patients with non-small cell and small 
cell lung cancer, (Buchanan et al. (2010). In the present study, total HADS total scores indicated that 
 59 
 
 
the typical subject had normal levels of psychologic distress with the exception of six subjects (6.2%) 
who were currently under treatment for these conditions. The reason for these differences are unclear 
but likely reflects differences in sample characteristics, measurement tools, and potentially time since 
surgery since our sample included patients 2-12 months post-surgery. With the exception of the 
percentage of our sample residing in rural areas, situational factors were similar to those reported 
previously for lung cancer populations.  
4.4.3 Influencing Factors and Symptoms 
As predicted by the TOUS, physiologic and psychologic influencing factors influenced symptom 
distress, as with previous studies, patients with higher levels of psychologic distress reported higher 
levels of symptom distress (Barsevick et al., 2006; Lee, 2005; Sarna et al., 2008). Of the five 
physiologic influencing factors (age, gender, cancer stage, surgical procedure, and comorbidities), only 
younger age and higher cancer stage were significantly related to symptom distress. Because HADS 
sub-scale scores for anxiety and depression were highly correlated (r= .735, p=.01), only the total score 
was used. Higher levels of anxiety and depressive symptoms were significantly associated with higher 
symptom distress (rho = .763, p =.05). No additional physiologic factors (gender, surgical approach or 
CCI scores) or any of the situational factors (education, marital status, or place of residence) were 
significantly correlated with symptom distress.  
4.4.4 Symptoms and Performance 
As predicted by the TOUS, and reported previously in studies of lung cancer, (Barsevick et al., 2006; 
Cheng & Lee, 2011; Dodd, Cho, Cooper, & Miaskowski, 2010; Gift et al 2008), patients with higher 
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levels of symptom distress experienced worse functional performance. This finding further highlights 
the need to explore symptoms experienced by patients with lung cancer and the impact on daily life 
activities (performance).   
4.4.5 Interrelationships 
In the present study, subjects reporting higher total scores on the HADS also reported lower functional 
performance  (rho = -.676, p=.01). Contrary to expectations, age and gender were negatively associated 
with total HADS scores (rho = -.308, p <.01 and rho = -.263, p=.01, respectively) (Gift et al., 2004). 
Hence, younger and male subjects reported higher total HADS scores, reflecting greater anxiety and 
depressive symptoms.  
 Although significant relationships were found, it is important to note that the mean level of 
psychological distress in this sample was considered in the normal range (based on average HADs sub-
scores < 8) and only 10% of patients in this sample were deemed to have clinically significant levels of 
anxiety or depression.  Our sample may be healthier than those in other studies due to this study’s 
inclusion criteria, which required that patients meet criteria for lung cancer surgery, which offers the 
potential of cure. Also, subjects were excluded if they were diagnosed with metastasis. Further, subjects 
were eligible for study entry 2-12 months after lung surgery.  
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4.4.6 Limitations  
           Subjects enrolled in this study were recruited from one university affiliated thoracic surgery 
practice with experienced operators that may not be representative of other centers. Also, subjects were 
predominantly white and therefore findings may not be generalizable to other non-white racial or ethnic 
groups. Subjects with metastasis who were not eligible for lung cancer surgery were excluded from this 
study. These patients may be more likely to experience higher cancer stages, lower survival rates, and 
therefore, more symptoms, psychological distress and lower functional performance. 
4.5 NURSING IMPLICATIONS 
Even up to one year after surgery, in patients with no evidence of metastatic disease, symptom distress 
was prevalent. Due to the presence of multiple symptoms, a comprehensive approach is needed in 
clinical practice to identify where to focus interventions. The TOUS may be a useful guide for 
oncology nurses because it considers the complexity of the symptom experience -- the potential for 
concurrent symptoms, the factors that influence them and their impact on performance. We concur with 
Lee (2005) and Myers (2009), who concluded that the TOUS had clinical utility for nurses to examine 
the relationships between symptoms, their influencing factors, and impact on performance to help 
identify opportunities for improving the symptom experience.  
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4.6 KNOWLEDGE TRANSLATION 
Due to the complexity of lung cancer patients’ symptom experiences, the TOUS may provide clinical 
utility for nurses, as it reinforces the need to assess the presence of symptoms, degree of distress 
associated with the symptoms, factors that influence these symptoms, and impact of symptoms on 
performance.  
 
 
 63 
 
 
5.0  STUDY II: POST THORACOTOMY PAIN SYNDROME (PTPS) FOLLOWING 
SURGERY FOR LUNG CANCER: PREVALENCE, CHARACTERISTICS AND IMPACT ON 
QUALITY OF LIFE 
 
Abstract 
Purposes:  Most prior studies examining persistent pain following surgery for lung cancer included few 
patients undergoing a minimally invasive approach. Several studies have proposed a neuropathic origin 
for this outcome. However, there has been limited exploration of this consequence using standardized 
instruments. We therefore compared the symptom experience and impact of symptoms on quality of 
life in patients with and without post-thoracotomy pain syndrome (PTPS). Methods:  Patients 
completed questionnaires to assess presence of pain (McGill Pain Questionnaire), neuropathic 
symptoms (Neuropathic Symptom Questionnaire), symptom distress (McCorkle Symptom Distress 
Scale), anxiety and depression (Hospital Anxiety Depression Scale) and quality of life (Functional 
Assessment of Cancer Therapy-Lung). Results: The majority (54.6%) reported symptoms associated 
with PTPS, with no significant difference between surgical procedure groups (p=.398). Excepting 
younger age (p=.009), no demographic or surgical characteristic differentiated patients with and 
without PTPS. Patients with PTPS described their discomfort as pain only (15.1%), neuropathic 
symptoms only (30.2%) or pain and neuropathic symptoms (54.7%) at varied locations in combination 
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or singly (incision, chest tube and drain sites, shoulder). Scores on questionnaires differed between 
patients with and without PTPS for symptom distress (p <.001), anxiety and depression (p <.001), and 
quality of life (p=.009), with higher distress associated with PTPS. Discussion: Despite new surgical 
techniques, PTPS remains a common postsurgical complication and results in considerable distress. 
PTPS presents with varied symptoms, attributed to varied locations.  A focused assessment is needed to 
identify all experiencing this condition, with referral to pain management specialists if symptoms 
persist. 
5.1 INTRODUCTION 
Post-thoracotomy pain syndrome (PTPS) has been defined as pain that recurs or persists along a 
thoracotomy incision at least 2 months after the surgical procedure (International Association for the 
Study of Pain, 2011; Merskey 1986). A variety of surgical procedures have been reported to cause 
chronic post-surgical pain, with an estimated incidence of 20% to 50% (International Association for 
the Study of Pain, 2011). For post thoracotomy patients, the estimated incidence ranges from 5-65% 
with 10% of patients reporting severe pain, defined as a > 5 rating on a 10-point scale (International 
Association for the Study of Pain, 2011). First reported as a consequence of “war wounds of the chest” 
(Blades & Dugan, 1944, p.301), PTPS received limited attention until a seminal study conducted by 
Dajczman et al. (1991) reported the presence of post-surgical pain in a series of 56 lung cancer patients 
who were disease free up to 5 years after thoracotomy.  
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Notably, not all patients who undergo lung cancer surgery develop PTPS. The pathology of PTPS 
has been attributed to rib (Bayram et al., 2011; Landreneau et al., 1994), nerve (Bayram et al., 2011; 
Miyazaki et al., 2011; Benedetti et al., 1998), or muscle (Karasaki et al., 2009; Frola et al., 1995)   
damage from surgery or a chronic pain syndrome initiated by inadequate pain relief in the postoperative 
period (Demmy, 2009; Duale et al., 2009); however, the true origin remains unclear. Other potential 
causative mechanisms include nerve or muscle damage related to the insertion of chest tubes and drains 
(Grosen, Petersen, Pfeiffer-Jensen, Hoejsgaar, & Pilegaard, 2012; Mongardon et al., 2011). More 
effective acute pain management has also not been successful in eliminating this condition (Wildgaard 
et al., 2011). As well, newer video-assisted surgical techniques do not appear to result in a reduction in 
incidence (Furrer et al., 1997).  
 Most prior studies of PTPS enrolled patients who underwent standard open thoracotomy and did not 
compare neoplasm location, cancer stage, or cell type, as potential factors influencing access and 
therefore injury to muscles, ribs, and costovertebral joints. Although it has been suggested that 
minimally invasive thoracoscopic procedures may result in less injury and therefore less risk for PTPS, 
most prior studies included few (Karasaki et al., 2009; Tsuchida, Hashimoto, Saito, Koike, & Hayashi, 
2007; Furrer et al., 1997)  or no (Grosen et al., 2012; Duale et al., 2011; Guastella et al., 2011; 
Mongardon et al., 2011; Pluijms, Steegers, Verhagen, Scheffer, & Wilder-Smith, 2006)   patients 
managed using a minimally invasive approach.  
 Several prior studies have proposed a neuropathic origin for PTPS (Wildgaard et al., 2012; Duale et 
al., 2011; Magurie, Ravenscroft, Beggs, & Duffy, 2006; Pluijms et al., 2006). However, there has been 
limited exploration of this consequence using a battery of standardized instruments to rate pain 
intensity, symptom distress or impact on quality of life (Mongardon et al., 2011). The purpose of this 
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study was to compare the prevalence, characteristics, symptom experience, and impact of symptoms on 
quality of life in patients with and without PTPS.  Our sample included 51 patients who underwent a 
standard thoracotomy and 46 who underwent a minimally invasive thoracoscopic procedure. 
5.2 METHODS 
The study was conducted between August 2010 and November 2012 at the University of Pittsburgh 
Medical Center Cancer Clinics. The study was approved by the University of Pittsburgh Institutional 
Review Board and all participants provided written informed consent.  
5.2.1 Sample 
Inclusion criteria: 1) managed surgically for Stage I, II, or IIIa lung cancer without evidence of 
metastasis; 2) between 2 and 12 months post–surgery (conforms to definition of PTPS); and 3) greater 
than 40 years of age (lung cancer is infrequent in those younger and if present likely atypical). 
Exclusion criteria: 1) any other cancer diagnosis or metastatic disease (to avoid confounding 
symptoms), 2) inability to speak, read, or understand English (questionnaires were in English), and 3) 
presence of comorbidities such as dementia, or memory loss (limited ability to participate as 
informant).  
Study participants were selected from three of the fourteen hospitals in a university based 
surgical practice. A total of 1140 patients were screened, resulting in 112 potentially eligible subjects. 
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Two patients were not enrolled due to refusal. Of the 110 patients who provided informed consent, 13 
did not complete the study for the following reasons: 5 did not return instruments, 5 died, and 3 were 
no longer eligible due to new metastatic disease. Thus, the final sample consisted of 97 of 110 (88.1%) 
participants.  
5.2.2 Surgical Procedure 
Choice of surgical procedure was at the discretion of the operating surgeon. Aside from surgeon 
preference, reasons for selecting the surgical procedure included tumor grade, location, lymphovascular 
invasion, histology type, pleural involvement, size and surgical margins (Detterbeck, Lewis, 
Diekemper, Addrizzo-Harris, & Albert, 2013). A complete surgical resection with curative intent was 
performed in all cases. No patient received preoperative radiation or chemotherapy.    
5.2.3 Measures 
Participants were given 6 self-report measures that took an average of 30 minutes to complete, with the 
option to complete the instruments in clinic or at home and return them in a pre-addressed mailing 
envelope. Study participants provided informed consent before completing study instruments.   
McGill Pain Questionnaire (MPQ)  
This self-report questionnaire was the primary tool used to identify pain resulting from PTPS. It 
was chosen because it  assessed pain intensity (1-10 scale), rated quality and distress using 78 
descriptors classified into 20 groups and included a figure used to identify this distress at specific body 
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locations (McGill, 2009). Of the descriptors, only two (“numb” and “tingling”) were used to identify 
neuropathic symptoms in the present study. Because prior studies of patients after chest surgery noted 
that, not just the surgical area, but also chest tube and drain sites were areas of pain, the instructions 
were modified to request that patients mark and rate their postsurgical pain at three locations: incision, 
drain and chest tube sites. For this study an overall pain score was calculated based upon the incision 
pain score. Instrument reliability and validity have been established in prior testing (McGill, 2009; 
Graham, Bond, Gerkovich, & Cook, 1980).  
Neuropathic Symptom Questionaire (NSQ)  
Because the MPQ was deemed inadaquate to appropriately identify neuropathic symptom 
descriptors associated with PTPS, the NSQ was added after 51 subjects were recruited. The descriptors 
included in the NSQ were chosen based on the terminology used by patients during follow-up clinic 
visits and a literature review (Bousassira & Attal, 2011). When completing the NSQ, participants were 
asked to “describe their discomfort at the surgical site” and to rate the presence and severity of 
“tingling”, “numbness”, “increased sensation due to touch” and “increased sensation due to movement” 
using a numeric visual analog scale (VAS) with zero indicating no discomfort and 10 the worst 
discomfort possible. MPQ descriptors (numb and tingling) were used to identify participants with 
neuropathic symptoms for subjects enrolled prior to adding the NSQ.  
McCorkle Symptom Distress Scale (SDS) 
The SDS was a 13-item, self-report scale designed to assess the subjective distress associated 
with 11 cancer related symptoms e.g., fatigue, pain, insomnia, cough, breathing, using a Likert-type 
scale (1 = least distress to 5 = most distress) with a total score ranging from 13 to 65 (McCorkel & 
Young 1979). Higher scores indicate more distress. Ratings were summed to achieve a total symptom 
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score. McCorkle et al. (McCorkel & Young 1979) suggested that a total score of 25 to 32 indicate 
moderate distress and scores ≥ 33 indicate severe distress. This total score was the variable used in this 
study. Instrument reliability and validity of the SDS have been established in prior testing (McCorkle et 
al., 1998; McCorkel & Young 1979). 
Health History Survey (HHS)  
A researcher-designed self-report instrument was used to identify personal, social, and medical 
variations among patients. Personal information was provided by the participant and included age, 
gender, race, ethnicity and smoking history. Social information included marital and employment 
status. Information provided by medical record included tumor type, cancer stage, surgical approach, 
and surgical procedure.  
Charlson Comorbidity Index (CCI)  
The CCI was designed to assess the presence and type of 19 comorbid conditions (Charlson, et 
al., 1987). Each condition included in the medical history was assigned a weight (1-6 points) based on 
the strength of its association with mortality. No weight adjustments were made for age. Instrument 
reliability and validity have been established in prior testing (deGroot, Beckerman, Lankhorst, & 
Bouter, 2003; Charlson, et al., 1987). 
Hospital Anxiety and Depression Scale (HADS)  
This instrument was a 14-item questionnaire designed to screen for mood disorders (Snaith, 
2003; Zigmong & Snaith 1983). The HADS was comprised of an anxiety and depression symptom 
subscale. Each of the subscales contained 7 Likert response items scored 0 to 3, with some scores 
reversed. The total possible score ranged from 0 to 42. The total possible score for two sub-scores 
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ranged from 0 to 21. Scores have been categorized as normal (range 0-7), suggestive of a mild mood 
disorder (range 8-10), and reportable presence of a reportable mood disorder (range 11-21). Prior 
studies have validated use of similar screening tools to evaluate distress in lung cancer patients 
(Buchanan, Milroy, Baker, Thompson, & Levack, 2010; Carlson, Groff, Maciejewski, & Bultz, 2010). 
Instrument reliability and validity have been established in prior testing (Snaith, 2003; Bjellend, Dahl, 
Haug, & Necklemann, 2002; Zigmong & Snaith 1983). 
Functional Assessment of Cancer Therapy-Lung (FACT-L)  
The FACT-L is a self-report, 44-item questionnaire designed to measure quality of life for lung 
cancer patients (Cella et al., 1995). The FACT-L is comprised of 5 subscales that measure lung-related 
symptoms and physical, social, functional, and emotional well-being. Scores for each of the five 
subscales range from 0 to 28, with higher scores implying higher quality of life. Subscale scores can be 
summed to calculate a total score (0 to 176) (Cella et al., 1995). Instrument reliability and validity have 
been established in prior testing (Cella et al., 2002; Soni et al., 2002; Soni & Cella, 2002; Cella et al., 
1995).  
5.2.4 Symptom Categories 
Subjects were first divided into two categories consisting of patients with and without PTPS. No PTPS 
was defined as a MPQ score of 0 and no neuropathic descriptors. Next, patients with PTPS were 
divided into 3 subgroups to assist in exploring the neuropathic components of this condition. PTPS with 
pain only was defined as a MPQ score of greater than zero with no neuropathic descriptors. PTPS with 
neuropathic symptoms was defined as a MPQ score of 0 and one or more neuropathic descriptors. 
 71 
 
 
PTPS with pain and neuropathic symptoms was defined as a MPQ score of greater than zero and one or 
more neuropathic descriptors. 
5.2.5 Analytic Strategy 
Data analysis was conducted using SPSS Version 21 (2013, Armonk, New York). Missing data were 
confined to one subject who did not return the SDS and HADS and a second subject who did not return 
the FACT-L. Comparisons between participants with and without PTPS were made using Chi-Square 
or Fisher’s exact test, as indicated (Pallant, 2007; Tabachnick & Fidell, 2007). The Mann Whitney test 
was used to test for statistical significance between groups because responses were not normally 
distributed (Pallant, 2007; Tabachnick & Fidell, 2007). When significant differences were found, post-
hoc comparisons (Kruskal-Wallis) were performed to detect the point of difference (Tabachnick & 
Fidell, 2007). Statistical significance was set at p ≤ 0.05 for all variables. 
5.3 RESULTS 
 
5.3.1 Demographic and medical Characteristics 
The sample included 97 patients (47 men, 50 women) who ranged in age from 45 to 84 years (mean 
67.3 ± 9.7 years). The majority were Caucasian 89 (91.8%), married or living with a significant other 
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63 (64.9%), with half 49 (49.5%) having some college or technical training. A minority 23 (23.7%) 
worked either part or full time. Approximately half 46 (47.4%) lived in the city with the remainder in 
rural areas. These data are presented in Table 3. Only younger age showed a statistically significant 
difference between patients with and without PTPS (p=.009). Patients with PTPS were significantly 
younger than those without PTPS.  
Of the 97 patients, 59 (60.8%) were between 2 and 6 post-operative months and 38 (39.2%) 
between 7 and 12 post-operative months. Approximately half 51 (52.6%) underwent a thoracotomy and 
the remainder 46 (47.4%) a thoracoscopic procedure for Stage I 64 (66.0%), II 19 (19.6%), or IIIa 14 
(14.4%) lung cancer. Half of the patients 53 (54.6%) reported symptoms associated with PTPS, with no 
significant difference between those undergoing the two procedures (p=.398). All patients were disease 
free at follow-up interviews (2-12 months). Slightly more than half (57.3%) had a lobectomy and the 
remainder received either a wedge segmentectomy or sleeve lobectomy procedure. The sites most 
commonly resected were the right lung 51 (52.6%) and upper lobe 53 (54.6%). The majority were 
diagnosed with Stage I disease 64 (66.0%) and the most common neoplasm cell type was 
adenocarcinoma 60 (61.9%). There was no statistically significant difference between patients with and 
without PTPS for any examined medical characteristic.  
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Table 3. Between group comparisons (n=97) 
Variable No PTPS 
n=44 
PTPS 
n=53 
p-value 
Age (Years) Mean (SD) 70.1 (9.0) 65.0 (9.8) .009* 
Smoking (Pack Years) Mean (SD) 46.6 (41.4) 41.1 (30.4) .821 
Charlson Comorbidity  Score Mean (SD) 5.1 (1.6) 5.3 (1.3) .371 
Gender (Male) 50.0% 47.2% .471 
Race/Ethnicity (Caucasian) 95.5% 88.7% .203 
Married or steady partner 61.4% 67.9% .528 
Not employed 75.0% 77.4% .4886 
Some college or technical school 43.2% 54.7% .177 
Resident of rural area 56.8% 49.1% .289 
Time since surgery (2-6 months) 63.6% 58.5% .380 
Surgical Approach   - 
                Thoracotomy 50.0% 54.7% .398 
                Thoracoscopic 50.0% 45.3%  
Surgical Procedure   - 
                 Lobectomy 52.3% 60.4% .275 
                 Other Procedure 47.7% 39.6%  
Tumor Location   - 
                  Right lung 54.5% 50.9% .857 
                  Upper lobe 54.5% 54.7% .675 
Cancer Stage (I a & b) 70.5% 62.3% .149 
Cancer Cell Type (Adenocarcinoma) 61.4% 62.3% .087 
PTPS: post thoracotomy pain syndrome 
*Significant difference between patients with and without PTPS.  
 
5.3.2 Impact of PTPS 
Ratings of pain, symptom distress, anxiety, depression & quality of life in patients with (n=53) and 
without PTPS (n=44) are presented in Table 4. Patients with PTPS reported a relatively low rating of 
pain on the MPQ (3.3 ± 3.3). Although the majority 32 (60.4%) reported a pain score ≤ 3 (mild pain), 
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12 (22.6%) reported a score between 4 and 7 (moderate pain) and 9 (17.0%) reported a score > 7 
(severe pain). Patients reporting moderate or severe pain were being managed using a variety of 
medications.   
 
Table 4. Between group comparisons 
 
Instrument         No PTPS 
           n=44 
  Mean           SD 
        PTPS 
         n=53 
  Mean       SD 
 
p-value 
SDS Total Score 18.3 3.7 25.9 8.1 .000* 
HADS Total Score 5.4 5.4 10.1 7.6 .001* 
    Anxiety sub-score 3.1 3.2 5.4 4.3 .013* 
    Depression sub-score 2.2 2.6 5.0 3.9 .001* 
FACT-L Total Score 112.3 15.5 92.1 24.5 .009* 
    Physical sub-score 26.0 1.9 20.6 6.1 .001* 
    Social sub-score 23.3 5.7 21.5 6.3 .100 
    Emotional sub-score 19.9 4.3 18.8 4.6 .321 
    Functional sub-score 
    Lung related symptoms 
22.2 
20.8 
7.1 
4.9 
18.5 
19.2 
7.1 
5.5 
.006* 
.114 
 
PTPS: post thoracotomy pan syndrome; SDS: Symptom Distress Scale; HADS: Hospital Anxiety and 
Depression Scale; FACT-L: Functional Assessment of Cancer Therapy-Lung  
* Significant differences between patients with and without PTPS. 
 
 
Total SDS scores differed between patients with (25.9 ± 8.1) and without PTPS (18.3 ± 3.7), 
with patients with PTPS reporting significantly (p <.0001) more distress. Notably, both groups included 
patients who reported moderate distress (SDS score 25-32). These individuals included 4 (4.1%) 
patients who reported no symptoms associated with PTPS and 12 (12.4%) patients who reported 
symptoms associated with PTPS. Ten (10.3%) patients reported scores ≥ 33 (severe distress). All were 
diagnosed with PTPS and were offered treatment for this condition. These data are reported in Table 4. 
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Total HADS scores differed between patients with (10.1 ± 7.6) and without PTPS (5.4 ± 5.4); 
patients with PTPS reported higher total distress scores (p =.001) and higher sub-scores for anxiety 
(p=.013) and depression (p <. 001). Within the total group, 6 (6.2%) subjects reported at least one sub-
score > 11 for anxiety or depression, which is a reportable level of distress. All were currently under 
treatment for their symptoms and all were in the group that reported PTPS.  
FACT-L total scores differed between patients with (92.1 ± 24.5, range 43 to 136) and without 
PTPS (112.3 ± 15.5, range 66 to 135). Patients with PTPS reported lower ratings (p=.009) for quality of 
life. Scores for two of the five subscales were significantly different between groups. Patients with 
PTPS assigned lower ratings to sub-scores for physical (p=.001) and functional (p=.006), but not for 
social, emotional or lung related symptoms.  
5.3.3 PTPS Symptom Characteristics 
To further describe symptoms experienced by patients with PTPS, participants were divided into three 
subgroups – those reporting pain only (MPQ score), neuropathic symptoms only (NSQ score or MPQ 
descriptors “numb” or “tingling”) or pain and neuropathic symptoms (MPQ score + NSQ score). PTPS 
was reported by 53 (54.6%) participants. Of these, 8 (15.1%) reported pain only, 16 (30.2%) 
neuropathic symptoms only, and the remaining 29 (54.7%) both pain and neuropathic symptoms.  With 
the exception of smoking pack years, there were no significant between group differences for any 
variable examined. These data are reported in Table 5.  
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Table 5. PTPS subgroup characteristics 
 
 
Variable 
 
Pain Only 
n=8 
 
Neuropathic 
Symptoms 
Only 
n=16 
Pain + 
Neuropathic 
Symptoms 
n=29 
 
 
p-value 
Age (Years) Mean (SD) 63.5 (8.4) 69.2 (9.2) 63.0 (9.9) .110 
Smoking (Pack Years) Mean (SD) 70.0 (37.7) 36.3 (24.6) 35.7 (27.5) .027* 
Charlson Comorbidity Score Mean 
(SD) 
4.8 (1.8) 3.9 (1.1) 4.4 (1.2) .404 
Gender (Male) 50.0% 56.2% 41.4% .623 
Race/Ethnicity (Caucasian) 87.5% 93.7% 86.2% .742 
Married or steady  Partner 75.0% 68.8% 65.5% .875 
Not employed  75.0% 75.0% 79.3% .933 
Some college/technical   school 37.5% 68.8% 51.7% .311 
Resident of rural area 37.5% 56.3% 48.3% .682 
Time since Surgery (2 - 6 mos) 50.0% 68.8% 55.2% .588 
Location 
Right lung 
Upper lobe 
 
37.5% 
62.5% 
 
43.8% 
43.8% 
 
58.6% 
58.6% 
.210 
.485 
Cancer Stage (I a & b) 62.5% 50.0% 69.0% .430 
Cancer type  (Adenocarcinoma) 50.0% 75.0% 58.6% .131 
PTPS: post thoracotomy pain syndrome 
*Significant difference between patients with and without PTPS  
 
 
5.3.4 Types of Surgery 
In prior studies, surgical approach has often been implicated as a potential cause of PTPS.  Equal 
numbers of patients who underwent a thoracotomy or thoracospic procedure reported pain only.  
Approximately equal numbers of patients reported neuropathic symptoms only or pain and neuropathic 
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symptoms. There were no statistically significant differences between the three groups related to type 
of surgery. These data are shown in Figure 7.   
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Figure 7. Surgical approach characteristics 
 
Approximately equal numbers of patients, who underwent a thoracoscopic or thoracotomy procedure, 
reported either: pain only, neuropathic symptoms only, or pain and neuropathic symptoms. There were 
no statistically significant differences between subgroups.  
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5.3.5 Location of Discomfort 
PTPS participants were also asked to report the location of their discomfort (incision, chest tube, drain, 
shoulder, or some combination of these sites) which could be described as pain, numbness, tingling 
and/or generalized discomfort. These data are reported in Figure 8. The 8 patients reporting pain only 
cited three locations, incision, chest tube, and drain site. There were 16 patients who reported 
neuropathic symptoms only. All reported discomfort located at the incision site.  The 29 remaining 
participants reported both neuropathic symptoms and pain.  
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Figure 8. Discomfort location 
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Patients reporting pain only cited three locations - the incision, incision and chest tube, and 
incision and drain site. All patients who reported neuropathic symptoms only identified the incision 
site. The majority of patients reporting neuropathic symptoms and pain identified the incision site. 
Others identified the chest tube site, shoulder region, or a combination of these sites.  
5.3.6 Subgroup Ratings of Anxiety, Depressive Symptoms, and Quality of Life 
Because psychosocial experiences can influence PTPS (Buchanan et al., 2010; Carlson et al., 2010); we 
also explored the impact of anxiety and depression as determined by the HADS total score and 
subgroup scores in patients reporting pain only, neuropathic symptoms only and pain and neuropathic 
symptoms. The data are shown in Figure 9. Although those reporting pain tended to have higher HADS 
scores, there were no statistically significant differences between subgroup scores. 
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Figure 9. Anxiety and depression scores   
 
HADS total scores did not differ significantly for patients who reported pain only (11.4 ± 6.9), 
neuropathic symptoms only (6.6 ± 6.4) or neuropathic symptoms and pain (11.8 ± 7.9). Also, there 
were no significant differences in sub-scores for anxiety and depression between the three groups.  
Impact on quality of life was measured by the FACT-L. These data are presented in Figure 10. 
There were statistically significant differences between FACT-L total scores in patients who reported 
pain (84.5 ± 28.1, range 56 to 127), neuropathic symptoms (112.3.1 ± 16.8, range 79 to 136) or pain 
and neuropathic symptoms (95.9 ± 24.2, range 43 to 132). Those individuals who reported neuropathic 
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symptoms only reported higher well-being (p = .027) compared to those with pain only or both pain 
and neuropathic symptoms. 
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Figure 10. Quality of Life 
 
 
There were statistically significant differences between FACT-L total scores in patients who reported 
pain only, neuropathic symptoms only, or pain and neuropathic symptoms. Those individuals who 
reported neuropathic symptoms only reported higher well-being (p = .027) compared to those with pain 
only or both pain and neuropathic symptoms. 
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5.4 MAJOR FINDINGS 
There were four major findings in this study: 1) patients who underwent a thoracotomy or thoracospic 
procedure using current surgical techniques were equally likely to report symptoms consistent with 
PTPS; 2) patients who experienced PTPS had discomfort at varied locations (incision, shoulder, chest 
tube and drain insertion sites), 3) PTPS discomfort manifested as pain only, neuropathic symptoms 
only, or as combination of both; and 4) symptom distress and quality of life differed significantly in 
patients with and without PTPS.  
5.4.1 Prevalence of PTPS 
 In the present study, which excluded patients with lung cancer metastasis, approximately half (54.6%) 
of the patients reported symptoms consistent with PTPS when the definition was expanded to include 
pain, neuropathic symptoms or both. There was no significant difference in report of symptoms related 
to the type of surgery (p=.398) or time since surgery (p=.380). In the 1990’s, a survey of 343 patients 
managed at our Center reported no difference in pain 1-year following a thoracotomy or thoracoscopic 
procedure (Landreneau et al., 1994). Similar findings were reported by Furrer et al. 1997, from a 
matched study of 30 patients recruited during the same time period. In their study, 33% patients who 
underwent a thoracotomy and 36% of patients who underwent a thoracoscopic procedure reported pain 
or discomfort 3-18 months after surgery (Furrer et al., 1997). More recently, findings from two surveys 
(Wildgaard et al., 2011; Steegers et al. 2008) that included a total of 750 patients reported a similar 
prevalence of chronic pain following a thoracotomy (33%-40%) or thoracoscopic procedure (25%-
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47%) at 22-23 months following surgery. To evaluate the contribution of intercostal nerve damage to 
the development of PTPS, Miyazaki et al. 2011 assessed nerve function using a series of stimuli (2000 
Hz, 250 Hz and 5 Hz) for 24 weeks following surgery for lung cancer. Function of myelinated nerve 
fibers was significantly impaired following surgery that involved use of rib retractors but absent when 
these were not used, supporting the notion that these fibers are susceptible to damage by pressure or 
stretch (Miyazaki et al., 2011). Patients managed using video-assisted surgery without metal retractors 
reported no pain at 12 weeks following surgery. Conversely, approximately 70% of those undergoing 
video-assisted mini-thoracotomy with metal retractors and conventional thoracotomy reported pain. 
Although these findings hold promise as a means to reduce the prevalence of PTPS, there will likely 
continue to be extensive numbers of patients who experience this condition given the multiple factors 
that influence surgical decisions, including size of the lesion, ability to localize and remove the tumor, 
and surgeon preference.      
5.4.2 Location of Symptoms 
Consistent with prior findings, most patients reported pain or symptoms associated with neuropathy at 
the site of the incision. However, other sites were also mentioned, including chest tube and drain 
insertion sites and the shoulder. Mongardon et al. (Mongardon et al., 2011)   reported that 21 (32%) of 
65 thoracotomy patients noted more than one painful site, most frequently the incision and chest tube 
insertion site. Guastella et al. (Guastella et al., 2011)   reported pain localization in an area entirely or 
largely distributed within the T5/T6 dermatomes on the operated side. Half of their patients described 
pain in the mammary or sub-mammary area and the remainder in a more diffuse area, including the 
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sternal/parasternal area and drain insertion point. Grosen et al. (Grosen et al., 2012) identified sites on 
the anterior, posterior and lateral chest wall. These findings are important, as they reinforce the need to 
inquire about pain and discomfort at various sites on the chest wall.  In our study, two patients reported 
pain and neuropathic symptoms that were only present at the chest tube insertion site or shoulder 
region.  
5.4.3 Symptom Presentation 
PTPS can present as pain and neuropathic symptoms or both. We therefore categorized reports of 
discomfort into three categories - pain only, neuropathic symptoms only or the combination. In our 
study, most patients 29 (54.7%) identified a combination of symptoms. However, 8 (15.1%) identified 
pain only and 16 (30.2%) identified neuropathic symptoms only. Prior studies have reported a varying 
prevalence of neuropathic symptoms. Steegers et al. (Steegers et al., 2008) used a validated screening 
tool, the PainDETECT Questionnaire, to assess symptoms in 204 patients. At a median time of 23 
months following surgery, 23% were described as having definite neuropathic pain and 30% probable 
neuropathic pain. Guastella et al. (Guastella et al., 2011) evaluated 54 patients 6 months after 
thoracotomy and identified 29% with neuropathic pain and 70% with chronic pain using a symptom 
grading system and the DN4, a screening tool for neuropathic pain. Mongardon et al. (Mongardon et 
al., 2011) reported chronic pain in 48% of patients, neuropathic symptoms in 12% and 40% with 
neither pain nor neuropathic symptoms. These findings appear similar to ours, although comparison is 
difficult due to the various methods used to detect presence of symptoms.  
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Several validated questionnaires are available for use in detecting the prevalence of neuropathic 
symptoms and describing related characteristics (Bousassira & Attal, 2011; Bennett et al., 2007; 
Freynhage et al., 2006). Serial monitoring using these instruments is strongly recommended to permit 
comparison between centers in regard to prevalence of PTPS, descriptors associated with its 
development, and response to treatment.  In addition, there appear to be differences in ability to detect 
changes in tactile and thermal stimuli as well as side-to-side symmetry in patients with and without 
PTPS (Wildgaard et al., 2012). Further assessment of these differences may yield beneficial insights 
into causes of this syndrome.  
5.4.4 Symptom Distress and Impact on Quality of Life 
Although pain is a frequent complaint, the majority of patients identified their pain as mild with mean 
ratings in the range of 3.3 ± 3.3.  However, a substantial minority reported moderate (22.6%) or severe 
(17.0%) pain, consistent with findings from prior studies (Grosen et al., 2012; Guastella et al., 2011; 
Wildgaard et al., 2011). Using standardized instruments, we also found significant between group 
differences in patients with and without PTPS in regard to symptom distress, presence of anxiety and 
depressive symptoms and quality of life. All instruments used in this study were brief and, in our 
experience, required approximately 20-30 minutes to complete if all were utilized. Serial monitoring of 
symptom distress using standardized instruments, including pre-surgical baseline measurement, is 
highly recommended to elicit objective data regarding the contribution of pre-existing risk factors and 
response to various therapeutic initiatives.  Prior studies support high levels of symptom distress in 
patients diagnosed with cancer (Buchanan et al., 2010; Carson et al., 2010) that can be influenced by a 
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variety of factors, including time of surgery (Lehto, 2011), coping style (Prasertsri, Holden, Keefe, & 
Wilkie, 2011), and response to treatment (Shimizu et al., 2012). One large study of 1334 consecutively 
recruited lung cancer patients reported that 12.4% were classified with depressive symptoms based on 
HADS sub-scores (Shimizu et al., 2012).  Hence, it is particularly important to assess symptom distress 
at baseline and serially over time.  
5.5 LIMITATIONS 
Our study used a cross sectional design that limited assessment of symptoms to a single time point. It is 
possible that symptoms may have differed over time. However, we found no difference in the number 
of patients reporting symptoms of PTPS based on time since surgery. The sample was recruited from a 
high volume academic service specializing in thoracic surgery. Results may not be generalizable to 
other practice settings. Approximately half of the subjects did not complete the NSQ, as it was added 
mid-study. MPQ descriptors (“numb”, “tingling”) were used prior to adding the NSQ. Patients with 
PTPS or subgroups may have been over or underestimated using this approach. Finally, we did not 
distinguish between muscle sparing and open thoracotomy nor did we distinguish between video 
assisted and robotic thoracoscopic surgeries.  
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5.6 CLINICAL IMPLICATIONS 
Absent new innovations in surgical technique, the syndrome of PTPS appears unlikely to diminish in 
frequency. Clinicians managing the care of these patients need to be aware of the various ways 
symptoms can manifest, i.e., pain only, neuropathic symptoms only or a combination of these factors in 
various body locations and question patients specifically regarding their presence. Referral to 
specialists in pain management should be considered if initial interventions prove ineffective in 
obtaining symptom relief. Brief questionnaires are available to guide evaluation of response to therapy 
(Bousassira & Attal, 2011; McGill, 2009; Bennett et al., 2007; Freynhagen et al., 2006), impact on 
activities of daily living (Ringsted, Wildgaard, Kreiner & Kehlet 2013), and symptom distress 
(McCorkle et al., 1998; Holmes, 1989), including presence of anxiety and depression (Snaith, 2003; 
Bjellend et al., 2002; Zigmong & Snaith 1983). This approach has been beneficial in the management 
of other conditions, as it provides objective data that can be compared over time both to guide treatment 
and assess efficacy of various approaches. Future studies, should focus on identifying best treatment 
approaches to manage the complex and varying symptoms seen in this patient population.   
 
 88 
 
 
APPENDIX A: IRB APPROVAL LETTERS AND CONSENT FORMS 
 89 
 
 
 90 
 
 
 91 
 
 
 92 
 
 
 
 93 
 
 
 94 
 
 
 95 
 
 
 
 96 
 
 
 97 
 
 
 98 
 
 
 
 99 
 
 
 100 
 
 
 
 101 
 
 
 102 
 
 
 
 103 
 
 
 104 
 
 
 
 105 
 
 
 
 106 
 
 
 107 
 
 
 
 
 108 
 
 
 
 109 
 
 
 
 110 
 
 
 
 111 
 
 
  
 112 
 
 
APPENDIX B: PERMISSIONS TO USE COPYRIGHTED MATERIALS 
 113 
 
 
 114 
 
 
 
 115 
 
 
 116 
 
 
 
 117 
 
 
 118 
 
 
 119 
 
 
 120 
 
 
 
 121 
 
 
 122 
 
 
 
 123 
 
 
 
 124 
 
 
APPENDIX C: COPIES OF STUDY MEASURES 
 125 
 
 
Symptom Distress Scale 
The following is a list of symptoms, each having five (5) different numbered statements. Think 
about what each statement says, then choose the one statement that most closely indicates how 
you have been feeling lately. 
 
Note: the statements are ranked from 1 to 5, where 1 indicates no problems and 5 indicates the 
maximum amount of problems. Statements 2 through 4 indicate your feelings somewhere in 
between these two extremes.  
 
PLEASE choose only one response for each symptom; do not skip any symptom. 
 
1. Symptom:  APPEARANCE 
No             The Most 
Problems                      Problems 
1   2   3   4   5 
My appearance My appearance My appearance My appearance  My appearance  
has basically has gotten a  is definitely  is definitely  has changed  
not changed. little worse.  worse than it  worse than it  drastically from 
      used to be, and used to be, and what it was. 
      I am not greatly I am concerned 
      concerned about it. about it. 
 
2. Symptom:  CONCENTRATION 
No             The Most 
Problems           Problems 
1   2   3   4   5 
I have my  I occasionally  I often have  I usually have I just cannot seem  
normal ability have trouble  trouble  at least some  to concentrate 
to concentrate. concentrating. concentrating. difficulty  at all. 
         concentrating. 
 
3. Symptom:  BOWEL 
No             The Most 
Problems               Problems 
1   2   3   4   5 
I have my  My bowel pattern I frequently have I am usually in  My present bowel  
normal  occasionally  discomfort from discomfort  pattern has changes 
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bowel pattern. causes me some my present  because of my drastically from 
   concern and  bowel pattern. present  what was normal 
   discomfort.     bowel pattern. for me. 
4. Symptom:  FATIGUE 
No              The Most 
Problems               Problems 
1   2   3   4   5 
I am usually I am occasionally There are  I am usually      Most of the time  
not tired  rather tired.  frequently periods very tired.      I feel exhausted.  
at all.     when I am   
      quite tired.   
5. Symptom:  PAIN (A) 
No                 The Most 
Problems                Problems 
1   2   3   4   5 
I almost never I have pain once I frequently have I am usually in I am in some  
have pain.  in a while.  pain -- several some degree  degree of pain 
      times a week.  of pain.  almost constantly. 
6. Symptom:  PAIN (B) 
No                 The Most 
Problems               Problems 
1   2   3   4   5 
When I do have When I do have The pain I do  The pain I do  The pain I have 
pain, it is very pain, it is mildly have is usually is usually very is almost 
mild.            distressing.  fairly intense.  intense.  unbearable. 
 
7. Symptom:  INSOMNIA 
No                 The Most 
Problems               Problems 
1   2   3   4   5 
I sleep as well I have occasional I frequently have I have difficulty  It is almost impossible 
as I always  spells of  trouble getting sleeping almost for me to get a 
have.  sleeplessness.  to sleep and  every night.   decent night’s sleep. 
      staying asleep.  
8. Symptom:  APPETITE 
No                 The Most 
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Problems               Problems 
1   2   3   4   5 
I have my  My appetite is  I do not really I have to force  I cannot stand 
normal  usually, but not enjoy my food myself to eat  the thought of 
appetite.  always, pretty like I use to.  my food.  food. 
  
   
9. Symptom:  NAUSEA (A) 
No                 The Most 
Problems               Problems 
1   2   3   4   5 
I seldom feel any I am nauseous I am often  I am usually   I suffer from nausea 
nausea at all. once in a while. nauseous.  nauseous.  almost constantly. 
 
10. Symptom:  NAUSEA (B) 
No                 The Most 
Problems               Problems 
1   2   3   4   5 
When I do have When I do have When I have  When I have   When I have  
nausea, it is  nausea, it is mildly             nausea, I feel  nausea, I feel  nausea, I am as sick 
very mild.  distressing.  pretty sick.      very sick.  as I possibly could be. 
 
11. Symptom:  COUGH 
No                 The Most 
Problems               Problems 
1   2   3   4   5 
I seldom   I have an  I often cough.  I often cough   I often have persistent 
cough.  occasional cough.    and occasionally and severe  
         have severe  coughing spells. 
         coughing spells.  
12. Symptom:  OUTLOOK 
No                 The Most 
Problems               Problems 
1   2   3   4   5 
I am not fearful I am a little  I am quite worried I am worried and I am worried and  
or worried.  worried about but unafraid.  a little frightened scared about  
   things.      about things.  things. 
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13. Symptom:  BREATHING 
No                 The Most 
Problems           Problems 
1   2   3   4   5 
I usually breathe I occasionally  I often have   I can hardly ever  I almost always have  
has basically have trouble  trouble breathing. breathe as easily severe trouble with 
normally.  breathing.     as I want.  my breathing. 
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McGill Pain Questionnaire 
On the character mark the location of your surgical pain in “red” and your surgery scars in “black” 
        
The words below describe pain. CHECK ONE word in each category if it best describes your present surgical 
pain. Leave out any group which does not apply. 
1 Flickering ____   7 Hot  ____   13 Fearful ____  18 Tight ____      
   Quivering ____        Burning ____      Frightful ____      Numb ____ 
   Pulsing ____      Scalding ____      Terrifying ____      Drawing ____ 
   Throbbing ____      Searing ____           Squeezing ____ 
   Beating ____       14 Punishing ____      Tearing ____ 
   Pounding ____   8 Tingling ____      Grueling ____ 
       Itchy ____      Cruel ____  19 Cool ____ 
2 Jumping ____      Smarting ____      Vicious ____      Cold ____ 
   Flashing ____      Stinging ____      Killing ____      Freezing ____ 
   Shooting ____           Frightful ____ 
    9 Dull   ____      Terrifying ____  20 Nagging ____ 
3 Pricking ____      Sore  ____          Nauseating ____ 
   Boring ____      Hurting ____  15 Wretched ____      Agonizing ____ 
   Drilling ____      Aching ____       Blinding ____      Dreadful ____ 
   Stabbing ____      Heavy ____          Torturing ____ 
        16 Annoying ____ 
4 Sharp    ____  10 Tender ____     Troublesome____  21 Brief ____ 
  Cutting    ____        Taut ____               Intermittent____ 
  Lancing ____        Rasping ____  17 Spreading ____      Continuous ____ 
        Splitting ____      Radiating ____ 
5 Pinching ____               Penetrating____   
   Pressing ____              11 Tiring ____      Piercing ____   
   Gnawing ____       Exhausting ____ 
   Cramping ____        
   Crushing ____   12 Sickening ____  
    Suffocating ____      
6 Tugging ____               What is your level of surgical area pain on a scale of 0 to 10? ____ 
   Pulling ____                What is your level of chest tube pain on a scale of 0 to 10? ____  
   Wrenching ____                What is your level of drain pain on a scale of 0 to 10? ____ 
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Neuropathic Pain Questionnaire 
In order to assess your neuropathy problem, we need to thoroughly understand just 
exactly what type of neuropathy you have, and how it may or may not change over time. 
You may have only one site of neuropathy, or you may have more than one, and we can 
discuss each site. 
 
1. How would you describe the discomfort at your surgical site on a scale from zero 
to ten? 
0 __________________________________________10 
No Discomfort      Worst Discomfort Imaginable 
2. How many sites feel this way?______ 
3. Please indicate where this discomfort is. Note the location of each 
site.____________________________________________________________________ 
4. Do you feel any numbness or tingling at this (point or denote to a specific site) 
surgical site? 
If yes for tingling 
How would you describe your tingling on a scale from one (1) to ten (10)? 
0 __ 1___2___3___4___5___6___7___8___9___10 
No Tingling       Worst Tingling Imaginable 
If yes for numbness 
How would you describe the numbness at your site on a scale from 1 to 10? 
0 __ 1___2___3___4___5___6___7___8___9___10 
No Numbness      Worst Numbness 
 
We are also interested in learning what circumstances cause change in these 
feelings. Please indicate the amount you experience each of the following in a scale 
from 0 to 10: 
5. Increased sensation due to touch: 
0 __ 1___2___3___4___5___6___7___8___9___10 
No Increase       Greatest Increase Imaginable 
6. Increased sensation due to movement: 
0 __ 1___2___3___4___5___6___7___8___9___10 
No Increase       Greatest Increase Imaginable 
7. Discomfort affects my daily activities 
0 __ 1___2___3___4___5___6___7___8___9___10 
No Affect       Cannot Perform Any Daily Activities  
Repeat 4, 5, & 6 for each site with discomfort 
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Health History Survey 
 
1. Please enter your age _____________ 
 
2. What is your sex? 
  __________Male     _________Female 
 
3. Do you consider yourself of Hispanic or Latino decent; that is of Mexican, Puerto 
Rican, Cuban, or Latin American decent?  ___________Yes 
 
4. Please choose one category that best applies to you? 
__________Asian    __________Black or African American   
__________ Native Hawaiian or Other Pacific Islander  
__________Native American Indian _________White   
5. What education level did you complete? 
 ________ Elementary School  ________High School or GRE 
 ________Technical School  ________Some College  
 ________Associates Degree  ________Bachelors Degree  
 ________Master’s Degree  ________MD or PhD 
 
6. What best describes your current marital status? 
_________Married   ______Divorced  _________Widowed 
_________Separated  ______Never been married  
_________Member of an unmarried couple 
 
7. What best describes your current employment status?  
 ________ Retired  ______Working Full-time     ______Homemaker  
 ________Student  ______Working Part-time     ______Unemployed 
 
8. Please enter a yearly income __________________________________  
 
9. What state do you live in?  
_________PA   ________Ohio  ________WV   __________Other, please identify. 
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10. What type of area have you lived in for most of your life?  
 _____________City (urban)  _______________Rural, farm 
 _____________Suburb of a city _______________Rural, nonfarm 
Cancer HISTORY (Please list all cancers, the cancer stage at diagnosis and the date of diagnosis): 
Cancer type Cancer 
stage 
Date 
   
   
   
 
 
Current lung cancer information:  
TNM Classification: ___________________________ 
Stage: _____________________________________ 
Tumor Type:  Adenocarcinoma, Squamous Cell, Other (specify)_________________ 
 Tumor Location: Right Upper Lobe, Right Middle Lobe, Right Lower Lobe,  
     Left Upper Lobe, Left Lower Lobe 
 
SURGICAL HISTORY (Please list your known type of operations and dates for lung cancer 
for example. Thoracotomy – open chest, Wedge-long incision along ribs, VATS – several 
small incisions): 
Operation Date 
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Prescribed medications: 
Name of medication 
 
Dose       Times per day Rate Effectiveness 
 
(1=very effective 
 10=ineffective) 
    
    
    
    
    
    
 
Home Remedies, Herbs 
 
Name of medication 
 
Dose       Times per day Rate Effectiveness 
(1= very effective 
 10= ineffective) 
    
    
    
    
    
    
 
Over the Counter Medications: 
Name of medication 
 
Dose Times per 
day 
Rate Effectiveness 
(1= very effective 
  10= ineffective) 
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Hospital Anxiety and Depression Scale 
 
 
Please choose one responses from the four selections; choosing an answer that best 
currently describes your feelings. You should give an immediate response and not 
thinking too long about their answers.  
_________________________________________________________________________ 
1. I feel tense or “wound up”:  
0   1   2   3  
Not at All   From time to time A Lot of the time Most of the Time 
2. I still enjoy the things I used to enjoy:  
0   1   2   3  
Definitely as much  Not quite so much  Only a little  Hardly at all  
3. I get a sort of frightened feeling as if something awful is about to happen:
 0   1   2   3  
Not at all  A little, but it  Yes, but not  Very definitely  
doesn’t worry me  too badly   and quite badly  
 
4. I can laugh and see the funny side of things:  
0   1   2   3  
As much as I   Not quite so  Definitely not so  Not at All  
always could  much now  much now   
5. Worrying thoughts go through my mind: 
0   1   2   3  
Only occasionally From time to time, A lot of the time  A great deal of  
    but not too often    the time 
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6. I feel cheerful: 
0   1   2   3  
Most of the time Sometimes  Not often  Not at All  
7.  I can sit at ease and feel relaxed:  
0   1   2   3  
Definitely  Usually  Not often   Not at All  
8. I feel as if I am slowed down: 
0   1   2   3  
Not at All  Sometimes  Very often   Nearly all the time   
9. I get a sort of frightened feeling like 'butterflies' in the stomach: 
0   1   2   3  
Not at All   Occasionally  A Lot of the time Most of the Time 
10. I have lost interest in my appearance: 
0   1   2   3  
I take just as   I may not take  I don’t take quite Definitely 
much care as ever quite as much  as much care as   
   care   I should 
11. I feel restless as I have to be on the move: 
0   1   2   3   
Not at all  Not very much Quite a lot  Very much indeed  
 
 137 
 
 
12. I look forward with enjoyment to things: 
0   1   2   3  
As much as ever  Rather less   Definitely than Hardly at all  
   than I use to  than I use to 
13. I get sudden feelings of panic: 
0   1   2   3  
Not at All   Not very often Quite often  Very often indeed 
14. I can enjoy a good book or radio or TV program:  
0   1   2   3  
Often    Sometimes  Not often Very seldom 
 
 138 
 
 
 
Functional Assessment of Cancer Therapy – Lung (FACT-L Version 4)  
 
Below is a list of statements that other people with your illness have said are important. Please circle 
or mark one number per line to indicate your response as it applies to the past 7 days. 
PHYSICAL WELL-BEING 
GP1 I have a lack of energy  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GP2 I have nausea  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GP3 Because of my physical condition, I have trouble meeting the needs of my family 
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GP4 I have pain  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GP5 I am bothered by side effects of treatment  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GP6 I feel ill  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GP7 I am forced to spend time in bed  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
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SOCIAL/FAMILY WELL-BEING 
0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Verymuch 
GS1 I feel close to my friends 
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GS2 I get emotional support from my family  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GS3 I get support from my friends 
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GS4 My family has accepted my illness  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GS5 I am satisfied with family communication about my illness 
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GS6 I feel close to my partner (or the person who is my main support)  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
Q1 Regardless of your current level of sexual activity, please answer the following question. If 
you prefer not to answer it, please mark this box and go to the next section. 
 
GS7 I am satisfied with my sex life  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
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Please circle or mark one number per line to indicate your response as it applies to the 
past 7 days. 
EMOTIONAL WELL-BEING  
0-Not at all, 1-A little bit, 2-Somewhat, 3-Quite a bit, 4-Verymuch 
GE1 I feel sad  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GE2 I am satisfied with how I am coping with my illness 
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GE3 I am losing hope in the fight against my illness 
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GE4 I feel nervous 
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GE5 I worry about dying  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
 
GE6 I worry that my condition will get worse  
0  1   2   3   4 
Not at all  A little bit Somewhat Quite a bit Very much 
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